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1A  SUMMARY 
 
Breast cancer is one of the most prevalent cancers affecting women. When early detected it 
has a very good prognosis, but once metastasis (cancer cells spreading out from the primary 
tumor site occurs) occurs, the average survival time decreases drastically. 
In recent years, there has been an explosion of life-saving treatment advances against breast 
cancer. Unfortunately most of our understanding regarding breast tumor stages is quite old, 
and few new markers for prognosis have been developed in the last few years. One of the 
most difficult aspects in the treatment of breast cancer in fact, is the absence of specific 
markers to identify the stage of the tumor, which complicates the design of specific and 
effective cures. 
In the past, most patients were treated in an overly aggressive way (oophorectomy, breast 
excision, or highly toxic chemotherapy), or in a too mild way resulting in increased mortality 
because of undetected metastasis. 
 The elucidation of the mechanisms responsible for the highly invasive potential cancer cells 
may help identification of specific targets for the diagnosis and treatment of cancer patients. 
Cell migration is one of the key events in invasive cancer and metastasis. Tumorigenic cells 
acquire this characteristic by undergoing a phenotypic mutation called epitheliomesenchymal 
transition (EMT). 
 
Our long-term goal was to elucidate the signal cascade leading to the EMT as a prerequisite to 
identify new markers specific for different stages of breast cancer. 
 The specific observations behind this project are that both Ras up-regulation which is 
frequently found in breast cancer patients, and TGF- stimulation, are able to transform 
normal epithelial cells into malignant fibroblastoid cells. The experimental focus of this work, 
therefore, was to elucidate the signaling pathways involving both, Ras protein and the TGF- 
receptor. 
PI3K was shown to play a central role in upregulating migration and invasion of cancer cells. 
PI3K is a family of signaling enzymes subdivided into three classes (I-III) on the basis of 
sequence homology and substrate preference.  
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Our experiments revealed that two members of class IA PI3Ks (p110  and p110 ) were 
able, when over-expressed, to activate downstream signaling proteins such as S6K, cdc42 and 
Rac and induce migration in cancer cells. 
 
At the same time an opposite role for the third member of the Class IA PI3K, p110 , was 
also evident.  In fact, p110  over-expression reduced epithelial cell migration, while its 
down-regulation, together with some downstream targets, (Rho, Akt), increased migration of 
breast cancer cells. These contrasting roles for PI3K isoforms, were confirmed by using 
specific pharmaceutical inhibitors as well as RNAinterference (RNAi). 
Together these results demonstrate that specific enzymes are involved in the acquisition of a 
malignant invasive phenotype of breast cancer cells.  We also proved that decreasing p110, 
p110, S6K and cdc42/Rac expression or increasing p110, AKT and Rho levels can reduce 
migration. 
 
In another study, we demonstrated that class II PI3K also plays an important role in cell 
migration and proliferation. In fact, we observed that PI3KC2 associates with the 
Eps8/Abi1/Sos1 complex and is recruited to the EGF receptor as part of a multiprotein signal 
complex. 
 
We also documented an over-expression of PI3KC2 in subsets of tumors and cell lines from 
acute myeloid leukemia, medulloblastoma and small cell lung cancer (SCLC). Here we could 
confirm a crucial contribution for PI3KC2 in inducing cell proliferation and survival. 
  
Our recent data then proved that class II PI3KC2 can be tyrosine phosphorylated and 
activated by Src. In the PI3KC2protein sequence several tyrosine residues were identified as 
possible site for phosphorylation by Src. Which residues play an essential role in activating or 
inhibiting  kinase activity, is still under investigation. 
   
Together these data regarding PI3K isoforms described new specific pathways to target in 
order to develop new anticancer therapies, although this would still require further studies. 
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1B  ZUSAMMENFASSUNG 
 
Brustkrebs ist die häufigste Krebsart, von der Frauen in der Welt betroffen werden. Die 
Früherkennung der Krankheit bietet den Patienten gute Möglichkeiten an, den Tumor zu 
bekämpfen. Sobald die Zellen sich vom primären Tumor abtrennen, um Metastasen zu bilden, 
nehmen die Überlebenschancen drastisch ab. 
In jüngster Vergangenheit hat es eine Explosion an lebensrettenden Behandlungen  gegen den 
Brustkrebs gegeben. Unglücklicherweise sind die Kenntnisse der Tumorstadien relativ alt und 
in den letzten Jahren wurden nur wenige neue Markers für Prognosen entwickelt. Eine der 
schwierigsten Aspekte bei der Behandlung von Brustkrebs ist der Mangel an spezifische 
Tumormarker um das Stadium des Tumors zu identifizieren. Dies erschwert die Entwicklung 
spezifischer und somit effektiver Behandlungsmethoden. 
In den vergangenen Jahren wurde die Mehrheit der Patienten entweder in einer sehr 
aggressiven Weise (Oophorectomy, Brustentfernung oder sehr hohe Dosen an 
Chemotherapie), oder in einer zu sehr milden Weise behandelt. Letztere führte auf  Grund der 
unentdeckten Mestasatse zu zunehmenden Todesfällen. Die Aufklärung der Mechanismen, 
welche den  Krebszellen ihre invasive Eigenschaften verleihen, kann uns helfen, spezifische 
Zielmoleküle für die Identifizierung und Behandlung von krebskranken Patienten zu finden. 
Migration ist ein Merkmal bei invasiven Krebszellen und Metastasebildung. Tumorzellen 
erwerben diese Fähigkeit, in dem sie eine phänotypisch Mutation durchmachen, die Epithelio 
Mesenchymale Transition (EMT) bezeichnet wird. 
 
Das langfristige Ziel der vorliegenden Arbeit war, die Aufklärung von Signalkaskaden welche 
Tumorzellen während der EMT führen. Dies ist die Voraussetzung um neue spezifische 
Markers für die Identifizierung der verschiedenen Stadien des Brustkrebses zu ermitteln. 
Die Tatsache, dass sowohl Ras-Protein up-Regulation (Ueberexpression) als auch TGF- 
Stimulation in der Lage sind,  Epithelzellen in Fibroblasten zu transformieren, wurde als 
Ausgangspunkt dieser Arbeit festgelegt. Der experimentelle Schwerpunkt dieser Studie lag 
daher darin, den Signaltransduktionsweg aufzuklären, welche das Ras-Protein und den TGF--Rezeptor beteiligt. 
 
 
 
 9 
                                                                                                                         Zusammenfassung                                                                                                                     
 
Frühere Studien belegen, dass PI3K eine zentrale Rolle bei der upregulating von Migration 
und Invasion von Krebszellen spielt. PI3K bilden eine Superfamilie von signalisierenden 
Enzyme, die nach Sequenzhomologie und Substratspezifität in drei funktionellen Klassen (I-
III) unterteilt werden.  
 
Unsere Untersuchungen offenbarten, dass zwei Mitglieder der Klasse I PI3Ks (p110 und 
p110)  in der Lage sind, nachgeschaltet Signalprotein wie S6K, cdc42 und Rac zu aktivieren 
und induzieren Migration in den Krebszellen, wenn sie überexpriemiert sind.  
Gleichzeitig wurde die gegensätzliche Rolle des dritten Mitglieds der Klasse I PI3K (p110) 
nachgewiesen. Die Überexpression von p110 verringerte Migration, während ihre 
Hemmung, zusammen mit anderen nachgeschaltet Target wie Rho oder Akt, Migration bei 
Brustkrebs wieder ansteigen liess.  
Diese gegensätzlichen Rollen der PI3K wurden durch verschiedene Untersuchungen mit 
gezieltem RNAinterference (RNAi) oder mit Hilfe spezifischer Inhibitoren. bestätigt 
Alle diese Resultate zusammen haben bewiesen, dass spezifische Proteine, an der Akquisition 
des bösartig invasiver Phänotyp der Brustkrebszelle beteiligt ist. Des weiteren haben wir 
bewiesen, dass eine abnehmende expression von p100, p110, S6K und cdc42/Rac oder 
eine Erhöhung der p110, AKT und Rho Levels, die Bösartigkeit verringern kann. 
 
 In anderen Studien haben wir bewiesen, dass die Klasse II PI3K auch eine wichtige Rolle bei 
der Migration und Proliferation der Zellen spielt. Tatsächlich haben wir beobachtet, dass sich 
PI3KC2 mit dem Eps8/Abi1/Sos1-Komplex verbindet und dass der EGF Rezeptor diese 
rekrutiert als ein Teil eines Multiprotein Signalkomplex. 
 
Neue Daten haben bewiesen, dass Klasse II durch Src phosphoryliert und aktiviert wird. 
Entlang der PI3KC Proteinsequenz  wurden mehrere Tyrosine als mögliche Stelle zur 
Phosphorylisierung durch Src erkannt. Welche Position eine unentbehrliche Rolle bei der 
Auslösung oder Verminderung der Kineaseaktivität spielt, wird immer noch erforscht.  
 
All diese Daten betreffend PI3K könnten zum Angriff auf einen neuen spezifischen 
Signalweg führen um neue und präzise Antikrebs-Therapien zu entwickeln, wobei diese 
Annäherung  weitere Studien benötigen würde. 
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2  INTRODUCTION 
2.1 Breast Cancer 
Breast cancer remains the most common malignancy among women in the Western world. 
It is not a disease of modern society, but has become a major health problem over the last 50 
years, affecting as many as one in eight women during their life time. The annual incidence 
rates in the low-resource countries are increasing up to 5% a year [1]. It is estimated that 
every year this type of tumor affects more than a million women all around the world, and 
around 400´000 die from this pathology. The incidence and gravity of this tumor are 
increasing with the increasing age [2]. 
In the early stage of development the breast is immature and structurally similar in male and 
female. In girls the first rapid period of development is puberty, where hormones such as 
progesterone and estrogen induce the breast tissues to rapidly grow and differentiate more [3]. 
Histological analysis reveals that the normal breast epithelium is composed of a relatively 
simple bilayer of inner luminal cells required for milk production and an outer layer of 
myoepithelial cells required for milk ejection. All the tissues are supplied with blood from a 
net of axillary, internal mammary and intercostal system of arteries and veins. It also contains 
several groups of lymph vessels [4]. Both the blood and the lymphatic system serving the 
breast, are responsible for cancer cell circulation and metastasis formation. More than 95% of 
breast cancers develop from the epithelial cells, arising from either the milk producing glands 
(lobular carcinoma) or the draining ducts (ductal carcinoma) [5]. 
The clinical manifestation of breast cancer can range from a localized tumor to a widely 
metastatic neoplasm, and is mainly divided into stages depending on size, localization and 
presence of metastasis [5]. 
STAGE 0:  This stage includes the ductal carcinoma in situ. Here the tumor is still confined   
                   in the duct and cancer cells have not invaded surrounding tissues. 
STAGE I:   The tumor measure at least 2 cm and some of the cancer cells spill out of the duct. 
                   From the biopsy there is no evidence of cancer cells in the lymph nodes. 
STAGE II:  The tumor is increasing in size, and measures around 5 cm maximum but still    
                   there is no evidence of cancer cells in the lymph nodes. 
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STAGE III:  Here the cancer has really taken hold in the lymph nodes. The size of the   
                     primary mass is not important, but if the lymph nodes are involved, the tumor is 
anyway classified as stage III [6]. 
 
STAGE IV:The tumor has spread out leading to secondary tumors. Tumor cells can 
disseminate in many ways, locally (to the underlying chest wall and related 
structures), regionally (via the lymphatic system cancer cells arrive to the 
axillary, supraclavicular or contralateral lymph nodes), systemically (via the 
bloodstream to distant sites including bone, liver, lungs, brain and  ovaries). 
The overall survival rate of patients with early advanced breast cancer (BC) has increased 
over the years largely because of adjuvant therapy [7-10]. Unfortunately the outlook for 
metastatic breast cancer remains extremely poor and patients mainly die from metastases 
rather than uncontrolled local disease. Therefore early detection of the tumor is a potentially 
important strategy for reduce mortality 
In general the treatment options that can be considered are surgery, radiotherapy, cytotoxic 
chemotherapy and hormonal manipulation to endocrine therapy. The chosen option is in 
general according to the tumor stage. For example, patients whose lesions are tightly focused 
can be treated with surgery. The aim of  this treatment is to achieve local control of the 
disease and prevent complications. It can be radical (mastectomy) [11, 12] or conservative 
(lumpectomy/quadrantectomy) [13-15].    
Very often surgical treatment is performed in combination with adjuvant therapy like 
radiotherapy (ionizing radiation) and chemotherapy (cytotoxic drugs). In general all the 
systemic therapies given after surgery to patients, who have no evidence of spreading of 
cancer, are called adjuvant therapy. When used as adjuvant therapy, after breast-conserving 
surgery or mastectomy, chemotherapy and radiotherapy reduce the risk of breast cancer 
recurrence [16]. Even in the early stages of the disease, cancer cells can break away from the 
primary breast tumor and spread through the bloodstream. These cells do not cause any 
symptoms, they do not show up on imaging tests, and they can not be felt during a physical 
exam. But if they are allowed to grow, they can establish new tumors in other places in the 
body. The goal of adjuvant therapy is to kill undetected cancer cells that have traveled from 
the breast [17]. Chemotherapy is also largely used in advanced breast cancer, before surgical 
therapies, in order to shrink large cancers so that they are more circumscribed and small 
enough to be removed [18].  
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The recognition of the role of estrogens in inducing breast tissues to rapidly grow and 
differentiate, opened the path to investigate their role in breast tumor development. The 
evidence of its role in stimulating breast tumor growth was quite immediate and this led  to 
the development of therapies based on endocrine intervention[19]. 
The predominant source of hormones in premenopausal women are the ovaries. In 
postmenopausal women they cease to produce them as a result of a complete loss of 
primordial follicles [20]. However, estrogens continue to be synthesized  through the 
conversion of circulating androgens (namely, androstenedione and testosterone) to estrogens 
(estrone and estradiol) [21]. Further to these evidences nowaday ovarian suppression is an 
established treatment for breast cancer in premenopausal women, achieved surgically 
(oophorectomy) [22], by radiotherapy and recently also medically (using luteinizing-hormone 
releasing-hormone antagonists such as Zoladex) [23]. This approach is potentially reversible 
and is associated with less morbidity than radiotherapy [23]. 
For postmenopausal patients selective estrogen receptor modulators (SERMs) and selective 
estrogen receptor down regulators (SERDs), which inhibit the proliferation stimulus on breast 
cancer cells are employed. Tamoxifen is the most investigated and most widely used 
representative of these agents, and has been introduced in the advanced disease, in the 
neoadjuvant and adjuvant setting, and for the prevention of the disease [22]. 
The most abundandt source of estrogens in postmenopausal women are the androgens present 
in the peripheral tissues. These are transformed in to estrogens by the enzyme complex called 
aromatase. Inhibition of aromatase is an important approach for reducing estrogen levels in 
postmenopausal women, thus reducing their effect on breast tumor cell proliferation [24]. In 
general anyway, endocrine or hormonal therapy has an effect only on those women whose 
tumors are positive for estrogen receptors (ER) and/or progesterone receptors (PgR). 
Therefore these receptors are usually measured in every primary breast cancer, as well as in 
metastatic lesions where the results would influence a treatment decision [25]. 
Another protein status that is now routinely tested is the HER-2/neu oncogene. Infact it 
became clinically relevant with the demonstration that HER2-povitive breast cancers are more 
aggressive and have a worse prognosis that HER2-negative tumors [26]. The HER2/neu 
proto-oncogene is a member of a family of genes encoding transmembrane receptors 
including the epidermal growth factor receptor (EGFR) and regulates important aspects of the 
growth and differentation of cells [27]. Recent new therapies, still under investigation, have 
focalized their attention on blocking angiogenesis. When the tumor grows in size, it requires  
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blood supply and for this it releases factors inducing  neovascularization [28]. By blocking 
factors or the specific receptors the growth of the tumor can be put under control. Numerous 
VEGF-based antiangiogenic therapies are currently being evaluated in phase II and III clinical 
studies, which should clarify their potential clinical use [29]. 
The VEGF protein is overexpressed in more than 30% of breast cancers and these tend to be 
hormone-receptor-negative, high-grade and aggressive tumors. On the other hand, these 
tumors are most likely to respond favorably to the other therapies [30]. 
As presented until now, the main prognostic factors that have been used to predict the course 
of the tumor development and thereby its treatment are patient age, tumor size, status of 
axillaris lymph nodes and hormone-receptor status. 
Because these factors, when used individually or in combination, do not yield prognoses with 
an extremely high degree of accuracy, the great majority of patients diagnosed with primary 
breast cancer are treated in an aggressive way even if only few presented at the end metastasis 
[31, 32]. Many treatments presented until now have very strong and delayed side effects, 
which are much worse than their advantages in breast cancer treatment. In order to avoid 
them, gene expression profiling can allow to predict the clinical course of breast cancer 
progression with higher accuracy [32, 33]. 
In addition, the outlook of the patients submitted to the current treatment is really poor. 
The treatments have been improved much faster in the past than how was done in the last 20 
years, where no effective new drugs were efficiently developed. Tumor gene expression 
profililing and thereby recognition of new targets could be an efficient alternative therapeutic 
strategy [33].  
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2.2 TUMOR SIGNAL TRANSDUCTION 
2.2.1  Tumorigenesis 
Cancer is a group of diseases where a cluster of cells stop to answer to the normal 
physiological input of cell control as a consequence of DNA damages. 
Cancer cells differ from normal cells in many important characteristics common to all tumors: 
1-  Uncontrolled and unlimited ability to proliferate [34]. 
2- Absence of contact and density inhibition  (normally cells proliferate until they reach a 
specific density after which they become quiescent) [35].  
3-  Reduced adhesion capacity, due to the capability to migrate more [36]. 
4-  Angiogenesis, a physiological process involving the growth of new blood vessels from 
pre-existing vessels [29]. 
5-  Resistence to apoptotic signals [37]. 
6-  Unilimited proliferative potential [38]. 
In normal cells, replication is a stimulus coming from the environment and able to drive cells 
in dividing into two by entering into mitosis. Mitosis is a cell process divided in 4 phases 
(G1/S/G2/M) separated by checkpoints that ensure the fidelity of the cell division. These 
checkpoints verify whether the processes at each phase of the cell cycle have been accurately 
completed before progression into the next phase. This means that the DNA is checked in 
each phase [39]. The increased incidence of cancer as a function of age has long been 
interpreted to suggest that genetic changes are require for tumorigenesis [40]. 
Very often in fact the checkpoint machinery recognises errors and then the damage response 
signalling pathway intervenes in repairing them [34]. The first step of this pathway consists in 
silencing proteins responsible for driving the cell in to the next phase,  in order to stop the cell 
cycle and give more time to the cell for repair the damage. Cells that fail to properly repair 
DNA damage and that undergo mitotic slippage will be eliminated by committing to the 
apoptotic program, thus preventing the emergence of cells containing an aberrant and unstable 
genome. Sometimes the molecules that link the mitotic checkpoint and the apoptotic program 
fail and the damaged cell goes on proliferating and giving rise to a population of cells 
carrying mistakes in their genome[39]. This is thought to be the first step of carcinogenesis, 
therefore when damages are  accumulated, the cell gives rise to a tumor. The first evidence of  
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tumorigenesis is that some cells start to proliferate in an uncontrolled way and without 
requiring the presence of stimulators in the surrounding. Several proteins involved in 
proliferation undergo mutations in their gene sequence, coding after that for a constitutively 
active protein that induces proliferation (oncogene) or for an ineffective inhibitory protein 
(tumor suppressor gene). The vital clues about oncoprotein functioning came from detailed 
studies of how normal cells regulate their growth and proliferation [41]. Therefore, to truly 
understand the complexity of oncoprotein function, we need to understand the details of how 
normal cell proliferation is governed. Normal cells recognise the presence of growth-
stimulatory factors present in the proximity via specific receptors expressed on the surface 
[42]. The received signal is internalised and integrated by complex circuits within the cell, 
which decide whether cell growth and division is appropriate or not.  
These extracellular signalling molecules can be very small and pass directly through the 
plasma membrane. Otherwise, as in the case of most of the signalling molecules, they need a 
receptor to translate their message from the outside to the inner cytoplasmatic cell 
compartment. All these receptors are composed in general by an extracellular domain that 
recognises and binds to the stimulatory factor. Then there is a transmembrane domain anchors 
the protein in the membrane and finally a cytoplasmic domain which is able to interact with 
downstream proteins, carrying on the signal. 
Cell surface receptors can be subdivided int groups depending on the way they transmit the 
signal. The most important groups are: integrins, tyrosine kinases, serine-threonine kinases 
and G protein-coupled receptor. 
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2.2.2  Tyrosine Kinase Receptors (RTKs) 
The study of tyrosine kinase receptors began with the discovery of the epidermal growth 
factor (EGF), the first of the growth factors to be discovered [43]. 
The EGFR consists of a number of extracellular domains forming the ligand-binding site [44], 
a transmembrane sequence and juxtamembrane domain, followed by an intracellular kinase 
domain and C-terminal domain [45]. This receptor is expressed in all epidermal and stromal 
cells as well as some glial and smooth muscle cells. It presents the ability to recognise and 
bind several ligands, including EGF itself, transforming growth factor (TGF-[46], and 
heparin-binding EGF (HB-EGF) [47]. Upon activation by its growth factor ligands, the EGFR 
undergoes a transition from an inactive monomeric form to an active homodimer even if there 
are some evidences that preformed inactive dimers may also exist before ligand binding. 
Since the EGFR has three known homologues, ErbB2 (Neu or HER2), ErbB3 (HER3) and 
ErbB4 (HER4), in addition to forming homodimers it may pair with another member of the 
family, to create an activated heterodimer [47]. This dimerization is essential in order to 
activate the kinase activity of these receptors. In fact only after dimerization these two 
receptor chains are able to reciprocally phosphorylate the tyrosine kinases present in their 
long carboxy terminal cytoplasmatic tail [47], inducing conformational change in the 
cytoplasmatic tail activating the signal [48]. In particular, several tyrosines that can be 
phosphorylated providing a docking sites for proteins containing SH2 (Src homology region 
2) and PTB (phospho-tyrosine binding) domains were identified [49]. The Src homology 2 
domain (or SH2 domain) is a protein domain of about 100 amino acids first identified as a 
conserved sequence region among the oncoproteins Src and able to recognise and bind 
phosphorylated tyrosine residues [50, 51]. More precisely it also recognises the amino acids 
present at the sides of the phosphorylated tyrosine making the binding site extremely specific. 
The evidence that the binding of a particular SH2 domain to tyrosine-phosphorylated proteins 
is dependent on the primary sequence around the phosphotyrosine (pTyr) came from studies 
on the PDGF (Platelet-derived growth factor) receptor, that is an other member of  the 
tyrosine kinase receptors, structurally similar to the EGFR [50, 52, 53]. Another important 
member of this group of receptors is the VEGF (vascular endothelial growth factor) receptor. 
This receptor was demonstrated to play an essential role in endothelial cells differentiation 
and, during development, in the vascular system morphogenesis [54]. As previously 
mentioned, VEGF is also essential in tumors that  
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need a process of neovascularization able to bring nutrients for expansion and progression 
[55].  This growth factor binds two high-affinity receptor tyrosine kinases, VEGFR1/flt-1 and 
VEGFR2/flt [56], both present in normal endothelial cells and upregulated during 
angiogenesis, despite VEGFR2 mediating most of the angiogenic functions attributed to 
VEGF [57].  VEGF has been liinked to poor prognosis in breast cancer [58]. Numerous 
studies have shown a decreas in patient outlook in those tumors overexpressing the VEGF 
receptor. The overexpression of VEGF may be an early step in the process of metastasis, a 
step that is involved in the "angiogenic" switch. 
Regarding its possible role in cancer, in general all the growth factor receptors can 
fundamentally be oncoproteins. In fact, since all the growth factor receptors can activate 
mitogenic signaling pathways, the idea of investigating the role and the sequence of these 
receptors in tumors was immediate.The first observation was an autocrine induction of these 
signals [59]. Rather than a growth factor signal sent from one cell to another located nearby 
(paracrine signaling), or sent through the circulation to distant tissues (endocrine signaling), 
cancer cells perform an autostimulation also known as autocrine signaling loop, in which cells 
produce their own mitogens. Tumors make and release growth factors to which they can also 
respond [60, 61]. Very often cells able to produce their own growth factors (autocrine 
proliferation induction), overexpress the relative receptor, or if tumor cells do not express it at 
all, they can even start to produce the mRNA and then the receptor [62-64]. Following 
dimerization and transphosphorylation models, there were new observations regarding the 
possible role of  growth factor receptors in inducing cancer formation. In fact, since these 
receptors are free to move in the plasma membrane, their increased numbers can cause them 
to bind frequently and these events are comparable to the dimerization events caused by 
ligand binding, triggering phosphorylation, receptor activation and signal emission, despite 
the absence of the ligand [65]. For instance, the EGFR receptor is overexpressed in a wide 
variety of human tumors, mostly carcinoma [66]. In such tumors, this can result in ligand-
independent receptor dimerization and activation, or alternatively, can make cancer cells 
hyper-responsive to low levels of EGF and TGF ligands [65]. This original theory was 
recently replaced by some evidences suggesting the involvment of G protein-coupled receptor 
(GPCRs) in EGFR activation [67].  In general overexpression of the receptor can induce the 
signal even without ligand. This overexpression can be due to mutations in the DNA, like 
amplification that has been demonstrated to occur in different tumor types [68, 69]. This was 
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present in more than 40% of the total solid tumors analysed. Several other genetic alterations 
like region deletion (like in the regulatory site of the gene expression), tandem duplication or 
point mutation were also identified [70, 71]. 
All these mutations, beyond inducing receptor amplification, can  code for a constitutively 
active form of it, active in a ligand-independent way [72]. Alterations like N-terminal 
truncation or tandem duplications, small deletion or some point mutation can also be 
involved. For instance, a point mutation can be present in the sequence coding for the 
transmembrane domain of the receptor and the resultant mutation could favor the constitutive 
dimerization of the two receptors chains. Some changes can be due to substitution of the 
tyrosine present in the catalytic domain with an amino acid able to mimic phospho-tyrosine, 
like Asp (aspartic acid) and Glu (glutamic acid) [73]. In this way, the receptor gives a 
continuous signal to downstream proteins for the induction of cell proliferation [74]. After 
growth factor stimulation, cells acquire the ability to not only proliferate more but also to 
migrate and to survive longer. This means that the receptor is able to transduce several types 
of  biochemical signals and that these signals impinge on a diverse array of cellular targets 
[75]. Understanding how signaling cascades operate was a crucial point to comprehend 
tumorigenesis. In fact, oncoproteins flood cells with a continuous stream of mitogenic signals, 
thereby the transformed state of cancer cells might well represent an exaggerated version of 
the responses that normal cells exhibit following exposure to growth factors. The first step 
following the activation of RTKs is the recruitment of adaptor proteins able to bind to the 
phosphorylated cytoplasmic domain of the receptor and in turn to induce activation of 
downstream proteins like Ras. The first adaptor protein identified is Grb2, a 25kD protein 
composed almost entirely of SH2 and SH3 domains [76]. Its SH2 domain is able to bind the 
activated cytoplasmatic domains of RTKs. This domain is approximately 100 amino acid-long 
and was identified in many cellular proteins with the role of binding phosphotyrosine residues 
present in the target protein. It is able to recognise the phospho-tyrosine and the amino acids 
surrounding it in a specific way [51, 53]. The Grb2 protein name, standing for growth factor 
receptor-bound protein 2, reflects the protocol by which this protein was identified, which 
was by screening a bacterial cDNA expression library with the tyrosine phosphorylated 
carboxy terminal region of the EGFR [76, 77]. Some adaptor proteines present only this SH2 
domain in their sequence, but most of the signalling proteins in general also present other 
domains responsible for driving on the signal cascade [78]. Frequently together with the SH2 
domain an SH3 domain, that commonly recognizes proline-rich sequences, is also present.  
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This domain was shown from many evidences to be able to interact with guanine nucleotide 
exchange factors and GTPase-activating proteins which in turn regulate the activity of small 
G proteins like the Ras superfamily [78-80]. Regarding the Grb2 protein, the SH3 domain 
turned out to be responsible for the binding to a second adaptor protein (Sos) that acts as a 
nucleotide exchange factor (GEF) [81]. RTK-Grb2 interaction is then essential for the 
translocation of Sos to the plasma membrane where it is closer to the Ras protein and can 
stimulate it to release GDP and bind to GTP, thereby activating it. Mammalian cells contain 
two closely related counterpart of Drosophila SOS: Sos1 and Sos2 [82]. Their protein product 
has a molecular mass of ~150 and is composed of several defined domains. Biochemical 
studies have established that Sos indeed functions as a guanine nucleotide exchange factor for 
Ras. Its catalytic activity is conferred by a 450-amino-acid domain (CDC25) that is highly 
conserved among different Ras exchange factors and highly specific for Ras [83]. Sos 
presents a second SH3 domain able to bind other adaptor proteins like Shc and E3b1 (or Abi-
1). These three proteins together form a complex in which they bind each other through SH3 
domains [84-86]. The NH2-terminal region of Sos contains regions of homology with Dbl 
(DH) and pleckstrin (PH) domains. This structure, the DH domain followed by a PH domain, 
is a typical motif of guanine nucleotide exchange factors that are specific for Rho GTPases 
family members (Rho, Rac, CDC42). The DH domain is the catalytic entity mediating the 
guanine nucleotide exchange on Rho GTPases, whereas the PH domain appears to be 
involved in the modulation of nucleotide exchange activity through several possible 
mechanisms, including subcellular targeting and intramolecular interactions. The existence of 
a DH-PH module in Sos, along with the abundance of evidence linking Ras activation to the 
activation of Rac, has created a framework for the idea that in addition to its guanine 
nucleotide exchange activity toward Ras, SOS might be endowed with a catalytic activity that 
promotes guanine nucleotide exchange on Rac [87]. In support of this idea, overexpression of 
the DH domain of Sos leads to the activation of Rac by enhancing the rate of guanine 
nucleotide exchange [88]. The interactions between proline-rich sequences in the COOH-
terminal region of Sos and the SH3 domain of Grb2 or E3b1 appear to serve as a device to 
segregate Sos into two distinct functional pools: one that catalyzes guanine nucleotide 
exchange on Ras and another that stimulates the guanine nucleotide exchange on Rac [89] 
(Figure 1). 
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Fig.1 Upon Growth Factor stimulation, Sos is able to act together with Grb2 as a nucleotide 
exchange factor for Ras or is recruited to actin filaments together with E3b1 and Eps8 
proteins and inducing then Rac activation. 
  
 
2.2.2.1   Ras 
The Ras protein was discovered in the 1980s and it was soon evident that it plays a critical 
role in controlling cell growth, Therefore Ras was one of the most intensively studied proteins 
of the past decade [90, 91]. Ras is a GTP-binding protein protein of around 170aa and like 
most of the transforming genes, Ras members were found by transforming NIH 3T3 cells 
with genomic DNA from different tumors [92]. The first Ras family member discovered is 
encoded by the v-H-ras gene and is the homologue of the transforming gene of a bladder 
carcinoma cell line (T24), the oncogene of the Harvey sarcoma [93, 94]. Afterwards it was 
discovered that the transforming gene Lx-1 of a human lung carcinoma cell line, is a human 
homologue of v-K-Ras, the oncogene of the Kirsten sarcoma virus [95]. One year later 
Shimizu et al. recognised the third and last member of the ras family, N-Ras-1 gene, the 
transforming gene of the SK-N-SH neuroblastoma cell line [96]. These three members of the 
Ras superfamily are structurally similar [91], but in reality the real number of this family 
members is not really clear since some authors argue about the presence of totally five                                  
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members (H-ras-1 and 2, K-ras-1 and 2, N-ras-1) [97],  while other authors describe four true 
Ras protein (H-ras, K-rasA, K-rasB, N-ras) [98]. Ras is attached to the cell membrane by 
prenylation, and is a key component in many cell signaling processes that at the end lead to 
cell growth and proliferation. Ras proteins are present in resting cells in an inactive form, a 
guanosine diphosphate (GDP)-bound state. Guanine nucleotide exchange factors (GEFs) 
induce Ras to release GDP and bind GTP, which causes its activation and the subsequent 
stimulation of downstream targets. Having performed these functions, GTPase activating 
proteins (RasGAPs) turn Ras off, inducing the hydrolysis of GTP to GDP [99, 100]. The 
binding state of Ras is basically regulated by two protein families, GTPase activating proteins 
(GAPs) and guanine nucleotide exchange factors (GEFs) like Sos that induce GDP-GTP 
change. The activation of a tyrosine kinase receptor recruits Grb2 and Sos. In this 
conformation Sos  is then able to bind to Ras through its CDC25 domain [101]. GEFs and 
GAPs play the role of accelerating a normal GDP-GTP exchange process. The mechanism by 
which they work has been a matter of debate [102-105].  
Activation of Ras requires translocation of the protein to the plasma membrane, where the 
signal start [106, 107]. Ras anchorage to the plasma membrane is possible due to post 
translational modifications, like prenylation, isoprenylation or lipidation, that result in the 
addition of hydrophobic groups. It is usually assumed that prenyl groups facilitate attachment 
to cell membranes, similar to lipid anchors like the glycosyl-phosphatidylinositol anchor 
(GPI). Some reports suggested the possibility that Ras induces signals not only from the 
plasma membrane but also from the Golgi or from the endoplasmic reticulum [108].  
All these evidences where found in cells where H-Ras was artificially overexpressed, in order 
to mimick the situation present in tumor cells [108, 109]. Oncogenic Ras was frequently 
found in different tumors but the gene mutated (H-RAS, K-RAS or N-RAS) varies widely 
depending on the tumor type [110]. K-RAS is however the most frequently mutated gene in 
tumors, for this reason expecially in breast cancer, downstream protein along Ras cascade, 
like p21 WAF1/CIP1, have been related to factors of established prognostic significance, and to 
clinical outcome after primary treatment in terms of disease-free interval and survival times 
[111, 112]. In fact, the contribution of aberrant Ras function to human malignancies is likely 
to be higher than that indicated by Ras mutation status, as the over expression of many 
tyrosine kinase growth factor receptors also leads to increased Ras-dependent signaling [110]. 
Like the normal Ras protein, the Ras oncoprotein is activated by binding GTP, but is then less  
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likely to be inactivated. Indeed the oncoprotein, due to point mutations was found to have lost 
virtually  
all GTPase activity [106]. In such a condition, it could be pushed into its active signal-
emitting configuration by upstream stimulatory signals and guanine nucleotide exchange 
factors and once in this activated state, the Ras oncoprotein is unable to turn itself off [113]. 
Most of Ras mutants were identify in that state and the gene mutations more often found are 
in the 12th, 13th and 61st amino acid of the protein, located around the cavity where the 
GTPase catalytic activity operates [114-116]. When the signal cannot be switched off, cells 
are continuously stimulated for growth and proliferation and specific downstream proteins are 
induced to transduce the signal. 
In general, Ras effector proteins are characterized by  presence of a Ras-binding domain also 
called RBD. At least three distinct RBDs have been recognized: 
- the RBD of RAF involved in the cascade of the MAP kinase [117]. 
- the RBD from PI3K the first kinase of the PI3K/AKT pathway [118]. 
- the RAS association (RA) domains of RalGDS and ARF proteins [119]. 
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2.2.2.2   MAP kinase, RAF/MEK/ERK pathway 
This pathway is only one of the several downstream signaling cascades activated by the GTP-
bound Ras protein. Soon after its discovery, over two decades ago, its important role in cell 
signaling was immediately evident [90]. In fact, antisense and dominant-negative Raf 
expression blocked tumor cell transformation induced by the RAS oncogene in cell culture 
[120, 121]. Raf was discovered by two groups independently as a retroviral oncogene, v-Raf 
or v-Mil, possessing a serine/threonine kinase activity [122-125]. Three mammalian Raf 
isoforms exist and are called A-Raf, B-Raf (BRAF), the most potent activator of the MAPK 
pathway and C-Raf the first to be identified and ubiquitously expressed [126]. The three 
mammalian Raf isoforms share domains of structural homology, designated CR1 (conserved 
region-1), CR2 and CR3 even if they present several functional variations. CR1 is located at 
the N-terminal region of the protein and contains two important domains both responsible for 
Raf membrane recruitment. The first is called RBD (Ras binding domain) and is responsible 
for the binding of Raf to Ras-GTP. The second common domain is defined as a zinc finger 
structure or cysteine-rich domain (CRD) that interacts with the lipid moiety on Ras. This 
binding gives a conformational activation signal to the RAF kinase domain [127-130]. The 
CR2 domain is the regulatory binding site and finally the CR3 domain is the C-terminal 
kinase domain that also contains a second binding site for regulatory proteins. As mentioned 
above the central role of Raf in tumorigenesis was immediately clear and now several 
different forms of Raf oncogenes are known. Among the 3 Raf members, BRAF is the most 
potent activator of the MAPK pathway in many cells [131]. Therefore, activating mutation in 
the BRAF gene are of particular importance in human cancers, especially in those that show a 
high prevalence of this mutation like melanma. 
Some of Raf family members present point mutations or a more severe deletion in the N-
terminal regulatory region, resulting in a constitutively active kinase. Thereby this activation 
results in a constitutive activation of its downstream targets MEK (MAPKK) and ERK 
(MAPK) [132-134]. Approximately 30% of all human cancers display evidence of 
constitutive activation of the Raf/MEK/ERK pathway.  
The dual specificity kinases MEK1/2 phosphorylate ERK1/2 on a tyrosine and a threonine 
residue leading to their activation. About 160 substrates have been described for ERK1/2, 
many of them localized in the nucleus and involved in the transcription of genes [135]. 
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The role of these downstream kinases are crucial for tumor growth and the Ras signal 
cascade. In fact transgenic mouse expressing Ras oncogene or overexpressing Erk proteins 
present a similar phenotype [136]. 
One important parameter that participates in the regulation and function of MAPK signaling 
is the subcellular localization of the protein cascade members [137]. It was shown that both 
ERKs and MEKs are localized in the cytosol of resting cells and that they translocate into the 
nucleus upon cellular stimulation [135]. However, while ERKs remain in the nucleus of the 
stimulated cells for up to 180 min, MEKs are rapidly exported out of the nucleus due to their 
nuclear export signals (NES). In the same region of NES, the MAPK-docking domain, 
responsible to bind and sequester ERK in the cytoplasm is also present. More precisely this 
domain recognizes the CD domain of the inactive form of  ERK [138, 139]. 
All of these docking sites are located outside the catalytic domain and determine the 
specificity of interacting molecules. In quiescent cells, MEK1/2 retains ERK1/2 in the 
cytoplasm through direct interaction [138]. Upon stimulation, ERK1/2 becomes 
phosphorylated at threonine and tyrosine residues and the latter results in a conformational 
change and in the dissociation of ERK1/2 from MEK1/2. ERK1/2 then translocates to the 
nucleus by three mechanisms: passive diffusion of a monomer, active transport of a dimer, 
and direct interaction with the nuclear pore complex [140, 141]. In the nucleus, ERK 
phosphorylates and activates several nuclear targets such as transcription factors. This nuclear 
location seems to be an essential prerequisite for proper cellular responses. After activation of 
its target, ERK must relocalize to the cytoplasm thereby MEK1/2 transiently enters the 
nucleus by passive diffusion and export ERK1/2 from the nucleus [142, 143]. The nuclear 
localization of MEK1/2 is also regulated by a rapid stimulus-dependent transport mechanism 
[143, 144]. As already mentioned above, several studies in vitro and in vivo have proved the 
essential role of MAPK pathway in normal cell proliferation and migration, thereby in tumor 
formation and development. For this reason, several approaches were employed to induce or 
silence the signals of each member of this pathway [145]. 
In general, whenever Ras activates a MAPKKK protein it is possible to identify it by 
monitoring the activation state of each of the downstream protein, as MAPKK and MAPK, 
since the activation of one member lead to the activation of the only identified direct 
downstream target (Figure 2). 
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Fig. 2 Activation of the ERK signaling pathway. In the nucleus, ERK induce the transcription 
of several nuclear targets. When ERK activity is turned off, MEK enters the nucleus, binds to 
inactive ERK and brings it back to the cytoplasm. 
 
2.2.2.3   PI3K/AKT kinase pathway 
Early studies on the plasma membrane identified the presence of membrane-associated 
phospholipids with a purpose fully unrelated to the maintenance of membrane structure [146]. 
Further studies, demonstrated that some of these phospholipids contain an inositol ring at their 
hydrophilic moiety (phosphatidylinositol, PtdIns) that can be modified by the addition of a 
phosphate group, producing a phosphoinositol ring [147, 148]. PtdIns consists of a 
 D-myo-inositol-1-phosphate linked via its phosphate group to a diacylglycerol tail that lies 
within the inner leaflet of the lipid bilayer of cells playing a role in anchoring the PtdIns to the 
cell membrane [147, 148]. The inositol ring presents five free hydroxyl groups and three were 
found be phosphorylation sites. Further evidences demonstrated that this phosphorylation was 
a crucial point for the beginning of a cascade of signals involved in important cellular 
functions like apoptosis, cellular proliferation [149], vesicular trafficking, cytoskeletal  
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organization and change in cell morphology [150]. The inositol moiety of phosphoinositides 
can be phosphorylated by several distinct kinases, each of which shows specificity in 
phosphorylatin a particular hydroxyl group of the inositol ring [151]. While several PI kinases 
have been discovered, the most important of these in cancer research is PI3K that is 
responsible for attaching a phosphate group to the 3'-hydroxyl group of the inositol moiety. 
The substrate of PI3K can be PtdIns or a phosphatidylinositol already phosphorylated in some 
of the other hydroxyl groups. Until now, there is evidence of only three different substrates: 
PtdIns, PtdIns4P and PtdIns(4,5)P2.  
The various 3-phosphorylated phosphoinositides that are produced by PI3k (PtdIns(3)P, 
PtdIns(3,4)P2, PtdIns(3,5)P2 and PtdIns(3,4,5)P3) function in a mechanism by which a 
selected group of signalling proteins, containing PX (phox homology) domain, pleckstrin 
homology domains (PH domains) and other phosphoinositide-binding domains, are recruited 
to the membrane and activated in order to transmit the signal downstream along the cascade 
[151]. This enzyme can be activated directly by cell surface receptors. In fact when a growth 
factor binds to the extracellular domain of an RTK, the receptor dimerizes and activates its 
cytoplasmic kinase activity. The autophosphorylated cytoplasmic domain of the RTK is a 
binding site for Src homology-2 domain-containing proteins. This is the case of PI3K that 
through its SH2 domains binds to the receptor and is thereby activated [152]. PI3K was 
demonstrated to be activated also by other cytoplasmatic proteins like Ras [153, 154]. Other 
reports also recognized other proteins that present either the SH2 domain or the SH3 domain 
and are able to transduce directly the signal from the RTK to the PI3K. A particular family of 
tyrosine kinase called Src were demonstrated to interact with PI3K even if this is not fully 
understood yet [155]. On the base of sequence homology and substrate preference in vitro, 
PI3K isoforms are divided into three different classes: class I, class II and class III. 
-class I: These PI3K enzyme members are composed of a catalytic subunit and an adaptor or 
regulatory subunit. Their preferred substrate in vivo is only PtdIns(4,5)P2 but in vitro 
they are also able to phosphorylate PtdIns and PtdIns(4)P. This class of enzymes 
presents catalytic subunits that bind to several regulatory subunits [156]. Catalytic 
subunits can be subdivided in subclass IA (including three members: p110, p110 
and p110), which are regulated by binding to RTKs and subclass IB (which contains 
only one member p110) that transduces signals originating from G-protein-coupled  
 
 
 27 
                                                 Introduction - Tumor Signal Transduction - RTKs 
 
receptors [157, 158]. The class IA catalytic subunits bind to the regulatory subunits 
(that includes p85, p85, p55 and p101) forming a heterodimeric complex [159].  
Subclass-IA is coupled with the p85 and  subunits, while p110is coupled with 
p101 or p84 regulatory subunit [159, 160]. The catalytic PI3K subunits (p110, 
p110, p110and p110) present the Ras binding domain, similar to the RBD found 
in Raf (already described previously) that is responsible for binding to Ras and 
activating the lipid kinase activity. The other important domains present in these 
subunits are the catalytic domain responsible for binding ATP and PtdIns, which is 
able to specify substrate preferences and a C2 domain, a protein domain of 80-160 
amino acid that posseses phospholipid-binding property. It was first recognized in 
PKC molecules and confers the phospholipid binding property to the protein. The C2 
domain is thought to be involved in calcium-dependent phospholipid binding and in 
membrane targeting processes such as subcellular localisation [161]. Protein 
presenting this domain are involved in signal transduction or membrane traffic [162, 
163]. The regulatory p85 subunits, on the other hand, present an SH3 domain and a 
structure of two SH2 domains separated by an inter-SH2 region, which serve as a 
docking site for the catalytic p110 subunit [159, 164].  
Another important difference that is worth to be mentioned about the catalytic 
subunit is that p110 and p110 are widely present in all the human cells.  
 
-class- II: Consist in three mammalian members, C2 and C2, and C2 of about 170kD. As 
the name already underlines, the characteristic of this class is the presence of two 
C2 domains, rather than only one as in the class I PI3K members [165]. 
The second carboxyl-terminal C2 domain seems to possess different properties in 
comparison with the other C2 domain also present in the other PI3K classes. 
Enzyme members of the class II also present a kinase domain responsible for PtdIns 
phosphorylation. Differently from class one, these proteins are composed by one 
subunit and they do not seem to bind any regulatory subunit. The members of this 
class have different preferences for the substrate compared to class I enzymes, 
PI3KC2 and C2 seems to prefer PtdIns but also act on PtdIns(4)P. 
-class-III: Class III are similar to II in that they bias the production of PI(3)P from PtdIns, but 
are more similar to Class I in structure, as they exist as a heterodimer of a catalytic  
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 (Vps34 homologue) and a regulatory (p150) subunit. Recent studies suggest that 
this class of PI3K is involved in diverse intracellular trafficking events including 
autophagy [166] and phagosome formation [167], internal vesicle formation within 
multivesicular endosomes [168] and transport at the nuclear membrane [169]. 
 
PI 3-phosphorylation is a balance of the action of PI3K and a phosphatase called PTEN 
(Phosphatase and Tensin homolog) that is able to dephosphorylate PtdInd(3)P thereby 
stopping the cascade of signal. PTEN is a protein that acts as a tumor suppressor gene and is 
found in almost all tissues in the body. The PTEN protein acts as a phosphatase to 
dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate (PtdIns (3,4,5)P3). The product of 
this enzymatic reaction is PtdIns(4,5)P2. This dephosphorylation is important since it results 
in inhibition of the AKT signaling pathway [170]. The structure of PTEN (solved by X-ray 
crystallography) reveals that it consists of a phosphatase domain, and a C2domain. The 
phosphatase domain contains the active site which carries out the enzymatic function of the 
protein, whilst the C2 domain allows PTEN to bind to the phospholipid membrane so that it is 
able to de-phosphorylate PtdIns (3,4,5)P3 [171]. 
Once activated by Ras or RTKs, PI3K phosphorylates the inositol ring of PtdIns. There are 
some proteins able to recognize and bind 3´-phosphoinositides, through two domains that are 
the FYVE zinc domain (the name derives from the four proteins where it has been found in: 
Fab1, YOTB/ZK632.12, Vac1, and EEA1) (80-90 aa) and the PH domain (100-120aa). The 
PH domain is a domain able to bind to phosphoinositides and their derivatives and was found 
in more then 100 different molecules [172-174]. The most important PH containing protein is 
AKT also called PKB. Once PI3K phosphorylates the inositol ring of PtdIns, AKT binds it 
through its PH domain and in this way it can also be phosphorylated and therefore activated. 
AKT/PKB is a serine/threonine-specific protein kinase and once activated proceeds to 
phosphorylate a series of protein substrates that have multiple effects on the cell as described 
below [175, 176]. AKT is a family composed of three members, AKT1, AKT2 and AKT3 
that present very similar sequences and sites of activation. The binding of AKT to 
PtdIns(3,4)and  PtdIns(3,4,5)P3  is possible through the PH domain [177]. 
In the AKT amino acid sequence two threonines and two serines were identified as possible 
sites of phosphorylation. Of these Thr308 and Ser473 were shown to be important for 
activation and are located, respectively along and after the kinase domain [178]. On the 
contrary the Thr450 and the Ser124 phosphorylation, located, respectively before (N- 
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terminal) and after (C-terminal) the kinase domain are not essential for the activation of the 
enzyme. Recent observations suggest that Thr450 controls the correct folding of the protein,  
then AKT is translocated to the plasma membrane and finally in the third step the enzyme is 
activated by Thr308 and Ser473 phosphorylation [178]. More precisely when PIP3 levels are 
elevated, AKT is recruited to the plasma membrane and phosphorylated in the "activation 
loop" (Thr308) by PDK1. In addition, AKT contains a highly conserved C-terminal 
hydrophobic motif (HM) that must also be phosphorylated for AKT activation [179]. Recent 
studies have indicated that TOR (target of rapamycin) complex 2 (TORC2) is responsible for 
HM phosphorylation [180, 181], implying a critical role for TORC2 in regulating AKT 
signaling and tissue growth. The kinase activity of TORC2 is provided by the protein kinase 
TOR, which is also found in a second complex, TORC1.  
Once activated by these phosphorylations, AKT/PKB proceeds to phosphorylate and activate 
a series of protein substrates that have multiple effects on the cell. 
The major biological effects that Akt/PKB has in cells are: 
 
- participating in cell survival by reducing the activation of the cellular apoptotic suicide 
program. 
The most important family of proteins involved in the control of apoptosis is called Bcl-2. 
The Bcl-2 family members are divided into 2 classes depending on their role in apoptosis, 
pro-apoptotic (Bax, BAD, Bak) or anti-apoptotic (including Bcl-2, Bcl-XL, and Bcl-w, 
among an assortment of others). They form heterodimers sequestering each other and, 
depending on which proteins are predominant in the cytoplasm, the apoptotic stimulus can 
start [176]. In this model if the pro-apoptotic proteins are the majority, they form 
homodimers, creating pores in the mitochondrial membrane through which cytocrome c is 
released [182]. This event, considered an early key event in apoptosis, acts as an essential 
cofactor in the cleavage and activation of the pro-caspase-9. Once activated, caspase-9  
initiates the caspase cascade and activates the executioner caspases [183]. Akt/PKB has 
been shown to inhibit cytochrome c release from mitochondria and thereby prevents 
initiation of the apoptotic cascade that lead to activation of caspases [184]. Akt is also able 
to phosphorylate the proapoptotic protein BAD, thereby inactivating it and inducing the 
release of the anti-apoptotic proteins allowing them to inhibit apoptosis [185]. Recently, the 
ability of AKT to phosphorylate and inhibit the activation of the pro-caspase-9 was also 
demonstrated [183]. Another important potential mechanism that Akt utilizes to regulate  
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this cascade is transcriptional control of the proteins involved in it, via its recently described 
effects on forkhead (FKHR) and possibly on NF-kB transcription factors [186]. 
 
- stimulating cell proliferation. 
The PI3K/AKT pathway was demonstrated to be involved in inducing cell cycle progression 
[187]. Cytoplasmic relocalization of nuclear proteins is a common phenomenon and has 
become as an established mode for their functional inactivation. It has been shown that AKT 
is able to phosphorylate p27kip1 and p21WAF1/CIP1 proteins [188] and Akt-induced 
phosphorylation of p27kip1 and p21 WAF1/CIP1 causes retention of them in the cytoplasm, 
thereby inactivating their ability to inhibit cell cycle [189-191]. 
 
- Regulation of protein translation and cell growth 
AKT was shown to be able to activate a central protein called mTOR, also known as FRAP, 
RAFT1 or RAPT [192]. mTOR is a protein composed by several distinct domains like the 
N-terminal region containing 20 tandemly repeated HEAT (Huntingtin, elongation factor) 
recognized responsible for protein-protein interaction and also in plasma membrane 
localization of the protein [193, 194]. Then there is FAT domain that serves as a scaffolding 
domain, followed by the FKBP-rapamycin binding domain, the kinase catalytic domain and 
a C-terminal FATC domain [195]. 
The most important downstream targets of mTOR identified are S6K and eIF-4E BP1 that 
respond in tandem to mTOR activation. S6K protein is present in two isoforms in 
mammalian cells (S6K1 and S6K2) and encoded by two separate genes [196]. A large 
amount of evidence suggests that once mTOR activates S6K, by phosphorylating it, this 
protein takes part in the control of cell growth via increasing mRNA translation [197].  
The generally accepted model is that S6K activation causes increased translation of 5' 
terminal oligopyrimidine tract (TOP) mRNAs, which encode components of the 
translational apparatus, including ribosomal proteins, elongation factors, and poly(A)-
binding protein (PABP) [198, 199]. Important ribosomal proteins that have been shown 
downstream S6K, are the S6 protein and eIF-4E pathway [200], They play the role of 
facilitating the binding of the ribosome to the 5‟-mRNA end and then increase protein 
translation [201]. 
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Figure 3. PI3K is activated directly by the RTK or by Src. After activation, PI3K is able to 
induce PIP3 formation and then activation or silencing of several downstream proteins 
involved in cell proliferation, apoptosis or protein translation. 
 
 
All the kinases presented until now as downstream of the PI3K/PTEN/AKT pathway, are just 
part of what seems to be involved. In fact new papers come out every day reporting about new 
roles for PI3K and AKT. Moreover, there is evidence that other than AKT/PKB other 
cytoplasmatic proteins use their PH domains to associate with PI(3)Ps, and that this 
association also induces their functional activation [202]. Among the PH-bearing cellular 
proteins are a group of guanine nucleotide exchange factors (GEFs) that act analogously to 
Sos, being responsible for activating various small GTPases that are relatives of the Ras 
proteins. These others GTPases belong to the Rho family of signaling proteins, which most 
well known members include Rho protein and its two relatives, Rac and Cdc42 [203, 204].   
 
 PIP3  
src PI3K PTEN 
AKT 
P 
Bad 
Apoptosis 
p21WAF1/CIP1 
/p27kip1 
Proliferation 
mTOR 
S6K 4E BP1  
Protein translation 
PIP2 
P 
RTK 
 32 
                                                 Introduction - Tumor Signal Transduction - RTKs 
 
Like Ras, these Rho operate as binary switches, cycling between a GTP-bound active 
signaling state and GDP-bound inactive state [205]. The Rho-GEFs, once activate, act on Rho 
proteins in the same way that Sos act on Ras. In particular, the Rho-GEFs induce Rho proteins 
to exchange GDP to GTP [206]. Once activated, Rho proteins have functions that differ 
strongly from those of Ras: they participate in reconfiguring the structure of the cytoskeleton 
and the attachments that the cell makes with its physical surroundings. Recently some authors 
have investigated the role that Ras could have in Rho-GEFs activation [207]. From what is 
evident until now, Cdc42 and Rac work in tandem in inducing the remodeling of actin 
filament at the migration front [208]. 
Rho also functions in the contractile actin-myosin filament assembly. This activity in 
migrating cells is located in the back tail where through contraction can induce the removal of 
the backfront (stress fibers). Rho Is also involved in the formation of focal adhesion 
complexes involved in the anchorage of the cell to the surrounding [209]. 
Rac and Cdc42 on the other hand were shown to be located at the front of migrating cells and 
are involved in the formation of cytoskeletal elongations like filopodia for Cdc42, and 
lamellipodia, ruffles for Rac [210-212]. 
According to this, Rho and Rac/cdc42 play opposite roles in cell migration and are also able 
to mutually regulate their activity. Mammalian Rac exists in 3 different isoforms, but most of 
the studies were done on Rac1 that is expressed ubiquitously, rather than Rac2 present in 
hematopoietic cell, and Rac3 present in the brain cells [213]. Furder explanations regarding 
this pathway are present in the section 2.5.  
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2.3   PI3K signalling in breast cancer 
The progression of primary mammary epithelial cells to a malignant phenotype involves 
multiple genetic events including activation of oncogenes and inactivation of specific tumor 
suppressor genes. In this regard, activation of the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway is thought to play a critical role in both the initiation and progression of human 
breast cancer. Activation of PI3K pathway can occur in response to a variety of stimuli that 
through the engagement of cell surface receptors then induce PI3K pathway activation. The 
active receptor triggers the recruitment of p85 regulatory subunit that then activates the 
catalytic PI3K subunit p110 [214]. 
Until few years ago, there were no evidences for activating mutations directly in PI3K genes. 
Therefore, this model could explain overactivation of this pathway and tumor formation. An 
increasing body of evidence, suggest that direct activation of the PI3K pathway can occur via 
activating mutations in the catalytic p110 subunit and this may play a critical role in the 
regulation of malignant breast cancer growth [215]. 
   
2.3.1 PI3KCA- Mutations in the PI3KCA gene, which encodes for the class I p110 
catalytic subunit, were recently discovered in many different human cancers including lung, 
brain and breast tumors [216-218].  Many authors reported about amplifications, deletions and 
more recently, somatic missense mutations, all increasing the kinase activity of  p110[219]. 
All these mutations seem to be located preferentially in exons 6, 9 and 20 that code for the 
kinase, helical and p85-binding domains [219, 220]. The first study described PIK3CA gene 
mutations in 30% of colorectal, brain and gastric cancers but only in a small percentage of 
breast cancers [216]. More recent data that considered a larger variety and number of primary 
breast cancers and breast cancer cell lines, reported that 70% of the samples presented 
mutations in the PI3KCA sequence [217, 221]. But this point is still a matter of discussion 
since more papers in accordance with either the preliminary data or the more recent data come 
out daily [222]. Together with this, there is another matter of investigation which results are 
extremely controversial. In fact some authors suggest that there is no association between the 
presence of PI3KCA mutations with other prognostic/clinical features of breast cancers, 
including histological subtype, oestrogen/progesterone receptor expression, Her2/neu receptor 
status, axillary lymph node  
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positivity and grade or stage of the tumor [221, 223]. This is in contrast with some others 
evidence reported recently [224]. In general the only point that seems to put everybody in 
agreement is that considering all the PI3K members, their alterations are present in most of 
the breast cancers [225]. All these controversial results are likely due to a number of factors 
including geographical influence, sample source, methods for DNA extraction and the stage 
of the tumor sample. Anyway more recent data, produced with new techniques and with 
breast cancer samples chosen with a higher accuracy, proved high frequence of PI3KCA gene 
mutations in breast cancer and a correlation with tumor stages. However, despite these 
discrepancies the high frequency of PI3KCA mutations and the discovery of hotspot 
mutations have important clinical implications for diagnosis, prognosis and therapy, in fact 
therapies targeted specifically against mutant PI3KCA can be developed [226, 227] 
 
2.3.2 PI3KCB- Not much is known regarding the role and the existence of mutations of 
this class IB protein kinase in cancer. Some authors demonstrated that there is a copy number 
alteration in more than 20% of late-stage primary ovarian cancers [228] but other mutations in 
this gene have not been reported. Its silencing with siRNA was decreasing tumor growth in 
glioblastoma, proving its crucial role in tumor progression [229]. There are no studies 
regarding mutations in PI3KCB and roles in breast cancer. 
 
2.3.3 PI3KCD- There are no evidences of mutation in this gene in breast cancer, some 
evidence and knowledge of over-expression are coming out now in neuroblastoma [230]. 
Regarding breast cancer, the only observation already published i s a 
higher migratory capacity to breast cancer cells  [231]. 
 
2.3.4 PTEN-This phosphatase is responsible for turning off the signal produced by 
PI3K. This means that together with activating mutations of PI3Ks, inactivating mutations of 
PTEN have also been frequently reported in cancer cells. The first evidences for mutations in 
PTEN came from investigations regarding the hereditary cancer predisposition Cowden 
syndrome (CS). This syndrome causes a huge amount of disturb but the most important was 
their high risk for developing cancers of breast and thyroid [232]. The genetic locus for 
Cowden syndrome was mapped to the 10q23 region that is the same where also PTEN gene is 
located [233]. PTEN mutations were discovered in 80% of the CS patients and from this a 
more accurate analysis of the locus revealed germline mutations in a great amount of tumors  
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[234]. In this locus many somatic deletions frequently found in tumors were described. In 
breast cancer, prostate cancer and glioblastoma biallelic inhactivation of PTEN, loss-of-
heterozygosity and point mutation in sometimes more then 50% of the tumor samples were 
reported [235, 236]. 
 
2.4  TGF Receptor 
Transforming growth factor- (TGF) was first identified as a component of sarcoma growth 
factors, secreted from Monoley sarcoma virus infected 3T3 cells that could mediate 
transformation (anchorage-independent cell growth) of non-neoplastic rat kidney NRK and 
murine AKR-2B fibroblasts [237]. The TGF receptor controls a diverse set of cellular 
processes, including cell growth, apoptosis, differentiation, migration, extracellular matrix 
(ECM) production, angiogenesis, immunity and epitheliomesenchymal transition (EMT) 
[238-240]. TGF family receptors are related to the tyrosine kinase reseptors, in that they have 
an extracellular ligand-binding domain, a transmembrane anchoring domain and a 
cytoplasmic serine/threonine kinase domain. It is important to mention that they have a 
substantial difference compared to RTKs receptors. In fact TGF kinase phosphorylates 
serine and threonine rather than tyrosine residues [241]. The TGF superfamily of growth 
factors consist of TGF members (1, 2, 3), Activins, Nodal and Bone Morphogenic Factor 
(GDF) and a few other minor members like BMP [242]. Regarding the receptor family there 
are only three members that are called type I, type II and type III. Among them only type I 
and II receptors are able to form heteromeric complexes and initiate intracellular signaling 
following ligand binding [241]. Until now 7 different mammalian type I and 5 different type 
II receptors are known and it seems that the heterodimers formed is different in depending of 
the specific grow factor activation [242, 243]. The type II receptor is constitutively 
phosphorylated on various serines, while type I is characterized by a region rich in glycine 
and serine (GS region), exactly before the kinase domain [241]. The TGF growth factor is 
recognized and bound by the TGFtype II receptor that then binds to the type I receptor. This 
leads to crossphosphorylation of the GS domain in type I receptor by the type II kinase 
receptor, which results in activation of the type I receptor kinase domain and initiation of 
downstream  signaling and phosphorylation of the Smad signaling mediators [244].  
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The most well characterized mechanism whereby TGF- superfamily members initiate signal 
transduction is via the phosphorylation and activation of the Smad proteins. Untill now eight  
Smad proteins are known in mammals that can be grouped into three classes based on 
function : 
- The Receptor activator Smad (R-Smad: Smad 1, 2, 3, 5, 8) [242]  
- The Common mediator Smad (Co-Smad: Smad 4) [242] 
- The Inhibitory Smad (I-Smad: Smad 6, 7) [242] 
The structure of Smad family members is very similar along the three classes. They contains 
three distinct regions, the Mad-homology domains 1 and 2 (MH1 and MH2) and a linker 
domain. The MH1 domain is located at the N-terminal region of the protein, while MH2 is at 
the C-terminal [245]. The MH1 domain is required to bind the DNA when translocated into 
the nucleus after activation. Actually Smad also needs to recognize and bind to other cellular 
factors (like Jun, TFE3, Sp1) to form transcriptional complexes which also bind to the DNA, 
and the binding region for these other transcription factors is through the MH1 domain [246, 
247]. Normally this domain is composed approximately of 130aa, but in the case of the 
Smad1 this sequence is extremely small and thereby is unable to bind the DNA. The MH2 
domain does not bind to the DNA and instead is a multifunctional region that mediates 
association with a wide variety of proteins. Some of them serve to provide specificity and 
selectivity to Smad function. In this region there is a basic pocket composed by basic amino 
acids that constitute a docking site for phosphorylated glycine/serine rich domains (GS 
domain) of type I receptors [248]. At the extreme C-terminus of the MH2 domain in R-smad, 
there is a SSXS (Ser-Ser-X-Ser) motif which is phosphorylated by activated type I TGF  
receptors [249, 250]. On the other hand, Co-Smad and I-Smad do not present this motif and 
thereby they can not be phosphorylated. R-smad phosphorylation is facilitated by other 
proteins including SARA (Smad anchor for receptor activation) and HRS/HGS (hepatocyte 
growth factor-regulated tyrosine kinase substrate) [251, 252]. Both these adaptor proteins 
contain the phospholipid-binding FYVE domain and function as adaptors to aid in recruitment 
of R-Smad to the TGF receptor complex. In the end, once the TGF receptor bind to the 
specific growth factor, it form a complex with TGF- I, phosphorylating its C-terminal 
domain [248]. This signal induces recruitment and phosphorylation of R-Smad members 
(Smad2 is the most commonly activated after TGF- stimulation). Phosphorylated Smad2  
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then forms a heteromeric complex with an other MAD-related protein, Co-smad4, and 
accumulates in the nucleus [253, 254]. Once in the nucleus, Smad2 also bind to the Forkhead  
activin signal transducer (FAST) through the MH2 domain of Smad2. The Smad4 MH2 
domain then binds to DNA at a site adjacent to that of FAST and thereby stabilizes DNA 
binding by the Smad-FAST complex that then induces specific gene expression [255]. 
signals also via the MAPK pathways and several other reports demonstrated that the Smad 
and MAPK pathways have functional interactions [256]. 
functions as an antiproliferative factor inhibiting cell growth by induction of apoptosis and 
cell cycle arrest (through p21WAF1/CIP1 and p15 protein upregulation and myc downregulation) 
[257]. In several tumors it 
correlates with the severity of the tumor grade. Tumor- ffect cells in 
proximity of the tumor, thus producing a microenvironment that promotes tumor growth, 
invasion and metastasis [258]. In many tumor, principally in breast cancers, TGF
the tumor cells directly, and regulates their capacity to proliferate and migrate. 
Especially regarding the complex process of cancer metastasis, the role of this growth factor 
has been documented. Recent studies demonstrate that Smad signaling is required for these 
TGF- -induced bone metastasis of breast cancer cells [259]. RNA-interference-mediated 
depletion of Smad4 in MDA-MB-231 breast cancer cell line inhibited bone metastasis in a 
mouse xenograft model, and this could be restored by ectopic expression of Smad4 [259]. 
Azuma et al. demonstrated that adenoviral overexpression of Smad7 in cultured breast tumor 
cells and in an in vivo mouse model of breast cancer inhibited the invasive phenotype of 
tumor cells [260]. In general Smad signaling contributes to the oncogenic activities of TGF-
in cancer cells that no longer respond to the antiproliferative signals of TGF-  
that Smad pathway is as a potential target to inhibit the invasion of malignant tumors [261]. 
The  to tyrosine kinase receptors and 
seems to be able to also induce the signal cascades presented in the previous paragraph. But 
regarding the ability of TGF- to activate Ras, PI3K and ERK there are still few informations 
[262] (For its description see 2.2.2.3). 
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2.5   Cell migration and metastasis. 
Despite improvement in detecting and treating primary tumors, long-term survival is often 
compromised by the development of metastatic lesions in unrelated tissues. In breast cancer 
the metastasis more often recognised are in brain and bones [263]. 
In the design of cancer treatments, the use of some adjuvant in order to  eradicate residual 
disease and reduce the risk of secondary tumors is increasing. Understanding the process of 
metastatic cell dissemination and tumor cell dormancy is therefore critical to design new 
effective treatments [264]. In breast cancer especially, metastatic dissemination of cancer cells 
requires the acquisition of properties that are not typically found in epithelial cells [265, 266].  
These properties include enhanced migratory behavior of the cells. As already described 
before there is a signal pathway that goes through RAS-PI3K-AKT and is crucial in inducing 
cell migration. The most important downstream family proteins responsible for it are the Rho 
family GTPases (For description, see 2.2.2.3). Together with Rho proteins another crucial role 
is played by the extracellular matrix (ECM). In tissue stroma, fibronectin and other ECM 
proteins provide adhesive signals as well as steric blockage of cell movement, to 
biochemically and mechanically restrict the movement of neoplastic cells from their primary 
tumor sites. Following loss of E-cadherin expression and other cell-cell contacts, many tumor 
cells exhibit altered expression patterns for the ECM receptors, along with increased secretion 
of matrix metalloproteases, to remodell tissue metrices and invade the vascular system [265, 
267]. All these changes together are defined as the epithelial to mesenchymal transition 
(EMT) and enhable neoplastic cells to escape from ECM-restrictions on motility. A widely 
expressed family of cell surface receptors responsable for cell adhesion to the extracellular 
matrix (ECM) and for cell-cell interaction are integrins [268]. All the family members are 
structurally composed by an  heterodimer [268]. Until now there are 14  subunit and 8  
subunits known and they could in theory associate giving more than 100 heterodimers. The 
hetorodimers founded until now describe are a more restricted [134]. Upon binding to specific 
ECM components, integrins are activated and clustered into regions of the plasma membrane 
termed focal contacts, or focal adhesions,nwhich anchor the actin cytoskeleton to the 
underlying ECM [269]. The clustering and dissociation of integrin cytoplasmic domains 
triggers the recruitment of a large number of membrane and cytosolic proteins to form 
submembrane plaques, termed focal contacts or focal adhesion, and is dependent on 
associated actin organization [270, 271]. 
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 Besides direct interactions with integrin cytoplasmic domains, an increasingly extensive list 
of cytoplasmic molecules have been found to be localized to focal adhesions, many of which 
interact indirectly with integrins and/or actin microfilaments [272]. Some of these are 
regulatory kinases including PI3K, PKC and tyrosine kinases such as FAK (focal adhesion 
kinase), Src and all together they orchestrate downstream proteins crucial for migration: Rho, 
Rac, cdc42. The model for cell migration is a highly integrated multi-step process that 
coordinates protrusion of the membrane and actin cytoskeleton at the migration front, 
assembly of focal contacts with which to stabilize attachment in the direction of coordinated 
motion, disassembly and release of focal contacts at the cell rear, and contraction with which 
to drive the cell on (Figure 4) [273, 274]. While represented as a step-wise process, each steps 
are occurring simultaneously, and provide mechanical feedback to the other aspects, thereby 
integrating and coordinating these four separate activities [275]. In polarized migrating cells, 
active membrane processes, including broad, sheet-like lamellipodia and thin, spike-like 
filopodia, are constantly extending and exploring around the cell front. Both of these 
structures are abundant in actin and actin-associated proteins, and their formation is tightly 
correlated with ongoing polymerization of actin filaments. Indeed, actin filaments are 
intrinsically polarized with fast-growing “barbed” or “plus” ends against the membrane, and 
slow-growing “pointed” or “minus” ends opposite the membrane, and this inherent polarity is 
used to drive membrane protrusion. In lamellipodia, filaments form a branching dendritic 
network, whereas in filopodia they are organized into long parallel bundles [208, 276]. In 
both cases, actual membrane protrusion is driven by actin polymerization that is regulated by 
the actin-related protein (Arp) 2/3 complex and actin severing proteins, such as actin 
depolymerizing factor (ADF, or cofilin) and gelsolin. In lamellipodial actin networks, Arp2/3 
complexes bind to the sides or tip of pre-existing actin filaments and nucleate filament 
branching [276]. Activation of Arp2/3 complexes is starting from Rac and cdc42. They 
activate downstream protein WASP/WAVE family members that then activate Arp2/3 
proteins and are themselves localized to the cell membrane [208, 277]. Protrusions in 
filopodia are thought to occur by a filament repetitive mechanism, in which actin filaments 
within a bundle elongate at their ends towards the filopod tip and actin monomers are released 
at the pointed ends near the base. The distinct organization of these protrusions appear 
particularly well-suited to separate functions: localized activation of the Arp2/3 complex in 
lamellipodia can direct a wide movement of the cell body in a particular direction during 
migration, whereas the filopodial extensions are well-adapted as exploratory sensors. For  
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maintenance of movement by membrane protrusions and also to sustain the lamellipodia, 
extensions must be stabilized by the attachment of integrins and formation of bigger focal 
contact structures. Those at the front of migrating cells are small focal complexes, which are 
Rac/cdc42-dependent (through WASP/WAVE and then Arp2/3), highly transient, and 
facilitate rapid migration by generation of strong propulsive traction forces [278, 279]. 
Proteins like  FAK and tensin were also identified early as components rapidly recruited to 
sites of integrin clustering [280]. FAK-Src signaling has been strongly implicated in turnover 
of focal complexes at the base of lamellipodia. Taken together, these studies underscore a 
central role for tyrosine phosphorylation in regulating protein-protein interactions critical to 
focal complex assembly and disassembly. While most focal complexes turnover at the base of 
lamellipodia, some undergo Rho-induced enlargement to form robust focal adhesions [281]. 
Focal adhesions are larger, elongated, take substantially longer to develop, are associated with 
stress fiber formation, and correlate with spreading and reduced motility. Differences in the 
molecular compositions between focal complexes and focal adhesions, aside from the 
involvement of Rho and some Rho effectors, are not well understood. Some observations 
suggest that Rho induces actin polymerization through a family of proteins, including DRF 
(diaphanous-related formin), mDia1 (mammalian homologue of diaphanous), and possibly 
mDia2. While Rho activity promotes focal adhesion maturation, its inactivation achived by 
Cdc42/Rac, appears to loosen adhesions, eventually leading to cell rounding [282, 283]. 
Coupling adhesion, protustion and actin organization are the myosin II-mediated contraction 
of the actin cytoskeleton [284]. This model incorporates a regulated actomyosin contractility 
and functional adhesion foci, which both generates force sufficient for locomotion and 
sufficient attachment to the ECM for the use of this force. 
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Fig.4 Cell migration and principal actors. During cell migration Rac and cdc42 proteins are 
located at the cell front and induce formation of  filopodia and lamellipodia. Rho and PTEN 
are working in the opposite direction and are located in the cell retraction area, inducing 
formation and elongation of structure involved in cell adhesion, like focal adhesion, stress 
fibres and microtubules.  
 
 
2.6   Src family tyrosine kinases. 
Src is a family of proto-oncogenic tyrosine kinases originally discovered by J. Michael 
Bishop and Harold E. Varmus, for which they won the Nobel Prize [285]. 
Src family of kinases (SFKs) comprises at least 9 proteins Src, Fyn, c-Yes, Fgr, Lyn, Hck, 
Lck, Blk and Yrk, all approximately 60 kD in molecular weight and with high sequence 
homology [286, 287]. The best known and most investigated member of SFKs is Src, but 
there is considerable evidence to support the idea that all members perform redundant 
functions. Src is the transforming (sarcoma inducing) gene of Rous sarcoma virus. The 
protein product is a cytoplasmic protein with tyrosine-specific protein kinase activity that 
associates with the cytoplasmic face of the plasma membrane [288]. 
This kinase has several different domains: an N-terminal (or SH4) domain for membrane 
association, a unique domain, SH3 and SH2 domains for protein-protein interactions, a 
catalytic domain and a negative regulatory domain [288]. 
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The inactive or closed conformation of this protein is achieved via phosphorylation of a 
conserved tyrosine residue (Y527 in avian c-Src), near the carboxyl terminal tail of the 
protein, which forms an intramolecular interaction with the SH2 domain [289]. Together with 
this  there is also an interaction between the SH3 domain and the short sequence of amino 
acids linking the SH2 and the kinase domain [290]. This complex structure limits the 
accessibility to both the kinase domain and the SH3-SH2 domains limiting the activation of 
this protein. For their activation, Src kinases require to be phosphorylated on Tyr(416/419) 
within the activation loop [291]. 
Several reports identified Src as a kinase involved in signaling from many receptor tyrosine 
kinases, including EGFR, IGF-R, PDGF-R and others [292]. 
This evidence suggested that in general, Src family kinases, can promote signaling from 
growth factors receptors in a number of ways. In fact these proteins seems to be involved in 
several cell responses like DNA synthesis, cell proliferation, receptor turnover and actin 
cytoskeletal rearrangements during cell migration [293]. 
Since Src is involved in so many cell functions, it has bong been investigated and it has been 
found crucial in inducing proliferation, angiogenesis, metastasis and EMT [294]. 
Upregulation of Src family members was shown be important in many tumor types, like 
colorectal, breast and lung cancer [295]. Anyway several authors proposed that Src is able to 
associate with related adhesion focal tyrosine kinase (RAFTK , also known as Pyk2) 
cytoplasmatic protein and together phosphorylate RhoGAP and RasGAP proteins involved in 
actin and cytoskeletal rearrangements [296].  
The outcome of Src binding to FAK (Focal Adhesion Kinase) is the phosphorylation of 
several tyrosine residues in FAK and FAK-associated proteins. FAK tyrosine phosphorylation 
sites that are targeted Src are several. Phosphorylation of tyrosine 925 has been mapped as a 
binding site for the SH2 domain of the Grb2 adaptor protein, which is believed to partially 
mediate activation of the Extracellular-regulated kinase (Erk) family of Mitogen Activated 
Protein (MAP) kinases [297]. The PI3K pathway has also been shown to be activated by Src. 
As already mentioned before, Src can be activated by several cell surface receptors, like 
EGFR. Recently authors demonstrated that EGF-stimulated epithelial cells migration requires 
the activation of a pathway dependent upon both PI3K and Src family kinases [298]. These 
and other data connecting Src activation to PI3K in migration, proliferation and other cell 
functions, are now starting to be published [299]. 
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3    Results 
3.1  Project Descriptions 
3.1.1 The catalytic class IA PI3K isoforms play divergent roles  
          in breast cancer cell migration 
Breast cancer remains the most common malignancy among women in the Western 
world and patient mainly die from metastases rather than uncontrolled local disease. In this 
project we investigated the molecular mechanisms involved in the acquisition of a malignant 
invasive phenotype by breast epithelial cells in response to oncogenic H-Ras transduction and 
TGF. We investigated the role of PI3K that from previous evidence appears to play a 
crucial role in this ability. We identified the PI3K  p110 and p110 as proteins able to 
induce this response through the activation of pro-migratory signalling pathways (S6K, 
Cdc42/Rac).  
Further investigations also identified PI3K  as regulator of an anti-migratory pathway, 
involving AKT and Rho proteins. These results unveiled new roles for the members of PI3K 
family enzyme and suggest new possible targets and markers for metastasis. 
 
In this manuscript I performed all the experiments aside from figures 8C and 8D (Olivier E. Pardo) 
  
 
3.1.2 Phosphoinositide 3-Kinase C2 Regulates Cytoskeletal Organization 
and Cell Migration via  Rac-dependent Mechanisms 
Phosphoinositide 3-kinases (PI3Ks) trigger activation of signaling pathways in response 
to extracellular stimuli that regulate diverse cellular programs such as cell survival, 
proliferation and migration, phagocytosis, and glucose homeostasis. 
Class I member were long investigated while instead the role of class II members is still 
unclear. In this report, we demonstrated that class II phosphoinositide 3-kinase C2 
(PI3KC2) associates with the Eps8/Abi1/Sos1 complex and is recruited to the EGF receptor 
as part of a multiprotein signaling complex also involving Shc and Grb2. Increased expression 
of PI3KC2 stimulated Rac activity in A-431 epidermoid carcinoma cells, resulting in 
enhanced membrane ruffling and migration speed of the cells. Conversely, expression of 
dominant negative PI3KC2 reduced Rac activity, membrane ruffling, and cell migration.  
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Moreover, PI3KC2 overexpressing cells were protected from anoikis and displayed 
enhanced proliferation, independently of Rac function.  
Taken together, these findings suggest that PI3KC2  regulates the migration and survival of 
human tumor cells by distinct molecular mechanisms. 
 
In this paper I performed the experiments in fig 9A and 9B. 
 
 
3.1.3 Targeting PI3KC2 impairs proliferation and survival in acute 
leukemia, brain tumors and neuroendocrine tumors 
 
While much attention has been given to the class I PI3K isoforms, little is known about 
the functions of class II PI3Ks in human cancer. This study was aimed at investigating the 
role of the PI3KC2 isoform in a panel of primary tumors and cell lines. Over-expression of 
PI3KC2 was detected in subsets of tumors and cell lines from acute myeloid leukemia 
(AML), glioblastoma, medulloblastoma, neuroblastoma, and small cell lung cancer (SCLC). 
Specific pharmacological inhibitors of PI3KC2or small interfering RNA (siRNA) impaired 
proliferation of a panel of cell lines and primary cultures from AML, brain tumors and 
neuroendocrine tumors. Inhibition of PI3KC2also induced apoptosis in AML and GB cell 
lines and sensitised the cells to chemotherapeuti
impaired the phosphorylation of downstream signalling mediators in AML. Together, these 
data show that PI3KC2 contributes to proliferation and survival in AML, brain tumors and 
neuroendocrine tumors and may represent a novel target in these malignancies.  
 
My contribution to this manuscript is figure 7 
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3.1.4 Investigation of the role of Src Tyrosine Kinase in the regulation of 
PI3KC2 
 
PI3KC2 is a class II PI3-kinase family member able to phosphorylate the D3 hydroxyl 
group of a downstream target phosphoinositide. Several important pathways involve 
 
different cell processes like proliferation, migration and actin rearrangement. From the 
sequence of this protein, 4 tyrosines were identified as possible site of phosphorylation (Y68, 
Y127, Y228, Y1541). Our previous studies proved a crucial role for Src proteins in activating 
PI3K class I members suggesting a possible second role for Src in regulating  also Class II 
members. On the base of this observation we used HEK293 cells and proved that Src was able 
to interact with PI3KC2 increasing substantially its lipid kinase activity. With migration and 
proliferation tests, we then identified a crucial involvement of Src and PI3KC2 in inducing 
the response in HEK293 cells. We went on investigating which of the possible 
phosphorylation sites are important for PI3KC2 activation. We finally concluded that Src 
activates PI3KC2, but when tyrosines 68 and 127 in the NH2 terminal domain of PI3KC2 
are mutated, the effect of Src on PI3KC2 activation was abolished in migration and 
proliferation assays. F-actin staining also confirmed that the mutants carrying phenylalanine 
instead of these two tyrosines were not able to induce the cytoskeletal organization that was 
evident in cells transfected with Src and PI3KC2 wild type. 
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3.2  Manuscripts 
3.2.1   The catalytic class IA PI3K isoforms play divergent roles  
in breast cancer cells (submitted to Oncogene) 
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3.2.2  Phosphoinositide 3-kinase C2
and Cell Migration via Rac-dependent Mechanisms 
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3.2.3  Targeting PI3KC2  impairs proliferation and survival in acute 
leukemia, brain tumours and neuroendocrine tumours  
          (submitted to British journal of cancer) 
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3.2.4     Investigation of the role of Src family Tyrosine Kinase  
in the  
 
3.2.4.1  Abstract  
 
-kinase family member able to phosphorylate the D3 hydroxyl 
group of a downstream target phosphoinositide. Several important pathways involve 
activated, transduce the signal, inducing 
different cell processes like proliferation, migration and actin rearrangement. From the 
sequence of this protein, 4 tyrosines were identified as possible site of phosphorylation (Y68, 
Y127, Y228, Y1541). Our previous studies proved a crucial role for Src proteins in activating 
PI3K class I members suggesting a possible second role for Src in regulating  also Class II 
members. 
On the base of this observation we used HEK293 cells and proved that Src was able to 
inter  With migration and 
proliferation tests, we then identified a crucial involvement of Src and 
the response in HEK293 cells. We went on investigating which of the possible 
2 
on and 
proliferation assays. F-actin staining also confirmed that the mutants carrying phenylalanine 
instead of these two tyrosines were not able to induce the cytoskeletal organization that was 
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3.2.4.2   Introduction 
 
PI3Ks are a family of enzymes able to phosphorylate the D3 hydroxyl group of the inositol 
ring in phosphoinositides. The substrate can be PtdIns or all the other phosphoinositides, 
already phosphorylated on the other hydroxyl group. These kinases are subdivided into three 
different classes (I-III). Class I are the most studied members and regulate several cell 
functions like cell proliferation, cytoskeletal structure, protein synthesis and migration [84, 
160, 300]. Recent observations also identified class II members as playing a crucial role in 
cell functions, but there are still few reports [84, 301-303]. 
Class II PI3Ks were first identified by sequence homology to other PI3Ks [304, 305]. The 
three members of class II (PI3K- -  and PI3K-C2 ) are monomers of high 
molecular weight, 170 KD [165]. The characteristic of this class of PI3K is the presence of 
two C2 domains, rather than only one as in the class I PI3K members. The second carboxy-
terminal C2 domain present in these proteins possesses different properties from the C2 
domain of the other PI3Ks. Differently from class I, these PI3Ks are composed by only one 
subunit and they do not seem to bind any regulatory subunit. Phosphorylation of different 
tyrosines, may control the activation of this enzyme, but nothing is demonstrated yet. Several 
possible sites of phosphorylation are present in the N-terminal and in the C2-terminal domain 
of all members, but which one is really important is still unknown [306]. Deletion of C2 
domain in fact, increase lipid kinase activity suggesting that it also act as a negative regulator 
of the catalytic domain [84]. 
Molecular interactions by which extracellular stimuli are linked to class II of PI3Ks are 
unclear at the present. Some results suggest that the RTKs are able to activate PI3K Class II 
members [84]. In this paper we show that Src is able to activate PI3KC2
that the two proteins are able to interact and that S
kinase activity. We also went further identify a possible role for Src and 
inducing proliferation and migration. 
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3.2.4.3  Materials and Methods  
 
Antibody and reagents—All the antibodies and the vectors were chosen and utilized according 
to[155] 
 
Transient expression in Mammalian cells-- HEK293 cells were grown to 50-60% confluence 
on 100mm dishes and transfected with cDNA constructs in pcDNA3 using calcium-phosphate 
protocol as already described [307]. The cells were harvested 24h post transfection and 
analysis for gene expression, protein kinase activity and plated for cell migration and 
proliferation. 
 
Immunoprecipitation--Cells grown on 150mm dishes were placed on ice and then lysed and 
immunoprecipitated as described in [308]. 
 
SDS-PAGE and Western blot analysis--Cells cultivated in 10 cm-dishes were lysed in lysis 
buffer, and SDS-PAGE and Western blot was performed as previously described [308]. The 
gels were transferred onto hydrophobic polyvinylidene difluoride membrane (Hybond-P; 
Amersham Bioscience). This membrane was than blotted with different antibodies. For 
detection, the enhanced chemiluminescence western blotting detection reagents (Amersham 
Biosciences) were used according to the manufacturer‟s protocol. 
 
 -Kinase Assays-- PI 3-kinase activity of the immunoprecipitates was assayed in 
according to [308] 
 
Cell Migration, Wound healing assays--Cells were platted in 12-wells culture plates in 
complete culture medium in a way to be confluent after 24h. At that time a wound was 
created using a disposable 200 µl micropipette tip in order to scrape off the cells. Pictures 
were then taken every 30 min for 8 h using a Leica9 DM IRBE Inverse, wide field 
Microscope (EMZ, University of Zurich) in order to follow the wound closure. In the case of 
transfected cells the transfection was performed 48h in advance and cells were plated 24h 
before the wound healing assay.  
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Cell Motility, time lapse assays--Cells were platted 24h before the experiment, in a 12-well 
plates in a way to be 30-40% confluent the day after. Cell migration was then monitored by 
taking pictures every 10 min for 12h. The program ImageJ was used to make a video. Single 
cells were followed and the speed of cells was measured under the different experimental 
conditions. 
 
Cell Proliferation 
Cells were plated at two different concentration 5x103/well and 10x103/well in 96-well plates 
and left to growth respectively 8h and 48h in complete DMEM. For every condition 8 wells 
were plated. The number of viable cells was then measured by means of an MTS assay using 
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, 
USA), according to the manufacturer‟s instructions. 
 
Immunofluorescence for F-actin- Cells were seeded on glass coverslips and let grown for 24 
h. In the case of inhibitors, the cells were then treated for 3 days. Then cells fixed in 
methanol, and permeabilized in 0,1% Triton X-100 were incubated with rhodamine-
conjugated phalloidin to detect F-actin. Nuclear staining was perfomed by incubating cells 
with DAPI before coverslip mounting. The coverslips were then washed in PBS and 
incubated in fresh Triton X-100 for 10-15 min in order to permeabilise the cells. After 
washing again in PBS1x an anti-actin antibody was added and after 20min was added also 
phalloidin and left for an additional 30 min. Coverslips were then washed in PBS, incubated 
with DAPI for 10 min and washed again PBS and finally fixed by Movieo on the cover slide. 
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3.2.4.4   Results 
 
 
Most of the knowledge regarding PI3K family of proteins is concerning class I members and 
less is known regarding class II proteins. In recent year a rapid increase in knowledge about 
cell signaling, drove our attention on the possible crucial role of Src protein in 
[309]. In order to investigate whether Src is 
93 
cells were transfected with Src and PI3
(Fig. 1). 24h after transfection cells were lysed and immunoprecipitated respectively for Src 
or myc. A Western blot analysis was then performed, revealing that in both the cases there is 
a coimmunoprecipitation of the Src-
proteins in cells. Further analysis regarding the phosphorylation state of the two proteins 
revealed that in the presence of co-
expressed alone or co-expressed together with Src kinase dead it was not phosphorylated 
anymore but is still present in the immunoprecipitation. Together this results clearly indicate 
that the two proteins interact in cells and that the phosphorylation by Src is possible only 
throw its catalytic activity. 
 
In vitro PI3KC2  
in cells  leading to the activation of the second 
protein we were interested in understanding if the two proteins interact directly and if Src 
ther proteins. 
To better answer to this question, the phosphorylation assay was performed also in vitro. 
only Src or ATP or both together and then incubated at 37° (Fig. 2A). From a subsequent 
 by Src was observed, the signal 
conditions where or ATP or Src 
phosphorylation. To examine the impact of Src-mediated tyrosine phosphorylation of 
in vitro, a kinase assay was performed (Fig.2B). 
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-incubated with Src and ATP and a kinase assay was subsequently 
perf
formation was present. Where the kinase wasn't previously activated there is almost no 
presence of PI(3)P. This showed that pre-phosphorylation by Src induces a significant 
increas  
 
Src- .        
inducing these characteristics. Already in human epithelial carcinoma cell line (A431) 
proliferation and migration [84]. We thereby proposed that kinase activation can be induced 
by Src. To prove this hypothesis HEK293 cells were transfected with Src and PI3KC2
separately or in combination and we investigated possible effects of these proteins interaction 
on migration (Wound Healing and Random Migration) and proliferation (MTS). The wound 
healing speed calculated, revealed a significant increase in migration in the cells transfected 
with both the proteins, while cells presenting the expression of only one of the two are not 
affected (Fig.3A). In order to confirm this data, increase in cell migration ability was also 
checked by random migration, confirming what the results observed in the wound healing 
(Fig3B). Part of transfected cells where plated for an MTS assay that also showed a relevant 
rise in proliferation of cells transfected with Src and PI3KC2
proliferation. 
 
 
  
On the base of these evidences we wanted to elucidate which tyrosine is phosphorylated by 
protein by Cell signaling, we created different mutants each of them carrying a single or 
combinations of mutations located respectively in the NH2 terminal domain or in the C2 
terminal domain (fig.4). As already mentioned before there are some specific tyrosines which 
are possible site of phosphorylation. Some evidences in tumors suggested that there are four 
specific tyrosine that can be phosphorylated in PI3KC2  
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located: three in the NH3 terminal domain (Y68-Y127-Y228) and one in the C2 terminal 
mutations or carrying two ore more mutations in different combinations. We already clearly 
ogether with Src, 
cells acquire the ability to proliferate and migrate more (Fig3 A-B). Thereby the mutants were 
tested in comparison with the wt and we transfected them in 293 cells together with Src. The 
results (Fig.5A) indicate that some of the mutants (2-3-6-7-9) were not affecting cell 
migration like PI3KC2
functional also in inducing proliferation. Together these results suggest that Mut2 (Y127F), 
Mut3 (Y228F), Mut6 (Y127F/Y228F), Mut7 (Y68F/Y127F/Y228) and Mut9 
(Y68F/Y127F/Y1541) abrogate Src-  
 
F-Actin staining confirms that Mut 2/3/6/7/9 are not active. 
After the results obtained in migration and proliferation assay, we focalized our attention on 
five of these mutants that seems to be inactive. Our interest was to investigate whether 
differences in migration reflected differences in cytoskeletal organization. 
In order to answer to this question, Mut2/3/6/7/9 plasmids were cotransfected with Src in 
HEK293 cells and after 24h an immunostaining for F-actin was performed. 
Normal cell shape appear generally rounded or just a bit elongated (Fig. 6A). The absence of 
actin accumulation around the borders reflected the absence of lamellipodia and ruffles, which 
confirmed the low migration capacity of these cells.  
After co
form of the cells presented long cytoplasmic elongations and irregular shape, similar to 
fibroblast cells (Fig.6B). Actin accumulation along the membrane demonstrated formation of 
ruffles and filopodia, typically present in migrating cells. In the pictures from cells transfected 
with the selected mutants (Fig. 6C), it was evident that there is no change in cell morphology 
when compared to wt cells and that there is almost no evidence of actin accumulation around 
the surface of the cell. These data confirm previous results regarding the inactivity of these 5 
mutants (Fig. 6C). They confirm that PI3KC2
shape, contributing to increase in cell motility. 
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3.2.4.5 Discussion 
 
PI3K protein members have been identify as key members of most of cell function like 
survival, proliferation, migration and gene expression regulation [310, 311]. 
Class I members have been long investigated since considered crucial for most cell types, but 
subsequently, Class II captured the attention of researchers too. 
Class II PI3K consists of three distinct isotypes: C2
one subunit containing all the domains, for protein binding, for the catalytic activity and the 
COOH- terminal C2 domain [165]. 
name to the protein family, since it seems to have special characteristics in comparison with 
the C2 domain also present in the other PI3K members. Recent observations demonstrate that 
deletion of the C2 domain increased the in vitro lipid kinase activity towards PI, suggesting 
that this domain may, therefore compete with the kinase domain for binding the PI substrate 
[308]. This evidence suggest that the C2 domain has a negative regulation on the lipid kinase 
activity of PI3KC2  
For class I PI3K it has been described that Src kinases interact with p85 regulatory subunit 
inducing activation of the lipid kinase activity [312]. 
On the base of this, a possible role for Src in inducing also class II PI3K activation was 
suggested.  In our in vitro and in vivo experiments it was clear that Src is really able to 
 that 
phosphorylation by Src was increasing its activity. 
The roles of 
activation could be important in migration and proliferation. We show here that co-expression 
d proliferation 
are extremely essential for both, normal and cancer cells, and the pathway responsible for 
them in not fully understood. Most is known regarding cell migration, suggest a crucial role 
for class I PI3K, but our results clearly provide evidences for an essential role also for 
PI3KC2
phosphorylations we selected four tyrosine as possible target for Src phosphorylation. 
These tyrosines are located respectively: three in the NH2 terminal domain and one in the 
COOH- terminal C2 domain. We thereby created several mutants and after migration and  
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proliferation studies, we hypothesized that mutants carrying Y68 and Y127 mutations present 
an ineffective activation by Src. This evidence kept our attention on these two tyrosine even 
if, some mutants carrying them together with other mutations, do not show any reduction in 
inducing migration and proliferation. We hypothesized that probably other mutation can 
 
This model is still under investigation and further experiments have to be performed in order 
appears to be involved in migration, and since migration clearly requires actin conformation 
changes, we performed other studies on actin remodeling which confirmed that these mutants 
are not functional. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
                                                                                                            Results – Manuscripts  
 
3.2.4.6   Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PI3KC2(myc)
   -      Src  SrcMF 
ip. Src 
MW 
4
 
Src 
20
 
20
 
PI3K C2 
ip. myc tag 
-   PI3KC2(myc) 
-     -      Src  SrcMF  
Figure 1 
Figure 1. In cell PI3KC2 phosphorylation assay. 
HEK293 cells were transfected with PI3KC2 alone or together with wt or kinase 
inactive Src. After 24h cells were lysed and immunoprecipitation for myc or Src 
was performed and then Western blot analysis was done. 
pTyr 
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Src       -         -            +         
PI(3)
OR
Src      +       +        -        +        +        -        - 
ATP    +        -        +       +        -        +        -     
Western blot pY 
Western blot PI3KC2 
PI3KC2 (1)           PI3KC2 (3) 
201 
Figure 2 
A 
B 
Figure 2. in vitro phosphorylation and kinase assay. 
PI3KC2 protein was mixed together with Src and ATP in combination, or 
separated.  After an incubation time, Western blot analysis was performed (A). 
A solution containing PI3KC2, PI and radioactive ATP was prepared. After 5 min 
of incubation a TLC was run and the PI(3)P presence was investigated (B). 
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Figure 3. Cell migration and proliferation analysis. 
 HEK293 cells wt or transfected with Src alone or in combination 
with PI3KC2 were analysed for migration by wound healing assay 
(A) or by random migration (B). Part of the transfected cells were 
plated for proliferation assay, MTS assay 
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Tyr residues to mutagenise: 
 
Y68, Y127, Y228, Y1541 
 
NH2 domain C2 domain Kinase core 
domain 
PIKinase 
PI3K C2
Figure 4 
Figure 4. PI3KC2 protein structure and mutants list. 
PI3KC2 contains several domains and the 4 most common 
phosphorylation sites in this protein  are located in the NH2-terminal 
domain and in the C2 domain. PI3KC2 mutants were created, 
containing one or more Tyrosine residues mutated to phenylalanine.  
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Figure 5. Mutants analysis in HEK293 cells. 
Cells were transfected with Src in combination with  
 
used for Random Migration assay (A). The rest 
 of the cells were platted for an MTS analysis. 
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       Figure 6 

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src
C2
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Figure 6.  
-10 in different 
 combination were plated and stained with fluorescent  
phalloidin (F-actin) (A,B,C). In this figure are shown the mutants  
inducing the most evident effect on F-actin organization. 
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4  Discussion 
 
The aim of this study was to investigate the role of Ras and TGF  in breast cancer.  
More than 95% of breast cancers develop from the epithelial cells, arising from either the 
milk producing glands (lobular carcinoma) or the draining ducts (ductal carcinoma) [5]. On 
the base of this evidence three different cell types were systematically compared (EpH4, 
EpRas, FibRas). They offered a new and attractive model able to mimic the three state of 
metastatic breast cancer development: epithelial cells (EpH4), oncogenic Ras-transduced 
epithelial cells (EpRas) and metastatic cells that already underwent the EMT transformation 
(FibRas) [313]. EpRas cells are epithelial cells transfected with the active form of the H-Ras 
gene. In fact it has already been shown that Ras play a crucial role in tumor formation [110]. 
It is now commonly accepted that epithelial cells over-expressing H-Ras protein generate 
human breast cancer cells [314]. Furthermore it was demonstrated that TGF  is a growth 
factor present in most breast cancer and that when added to cells already presenting H-Ras 
over-expression, it is able to increase cell migration and invasion [315, 316]. It was proved 
that these cells after treatment with TGF  undergo the EMT transformation characteristic of 
metastatic cells [317]. This model offers a novel approach for investigate the pathway 
involving TGF  and Ras in breast cancer and metastasis development. The use of 
pharmacological inhibitors in migration and proliferation experiments, revealed that the 
MAPK pathway was mainly involved in proliferation, rather then PI3Ks that revealed to play 
a crucial role in migration and invasion. Based on this result, the main focus of this project 
was to investigate the contribution of the individual PI3K isoforms in FibRas cells migration. 
The idea that the members of the PI3K superfamily have different roles in cell functions is 
already widely accepted. The data presented in this dissertation are in agreement with this 
idea and we further investigated it. We in fact demonstrated for the first time that class IA 
PI3K is crucial in FibRas signaling inducing cell migration, proliferation and actin 
rearrangements. In fact inhibition of p110  or p110  function by using pharmacological 
isoform-specific PI3K inhibitors or by short hairpin RNA (shRNA)-mediated silencing 
drastically impaired migration of FibRas cells. These class IA PI3Ks have been already 
suggested to contribute to the pathophygiology of ovarian cancer and also contribute to cell 
anchorage-independent growth [318, 319]. PI3KCA has been found mutated at high rate in  
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breast cancers [216, 217]. Despite all these observations, nothing is known about 
p110 specific pathway activation and all the data reported until now regard in general all 
 has been also proved as able to induce p53 activation and since this 
p53 is a crucial and amply studied oncogene, this gave much more emphasis to the possibility 
of a key role for PI3K class IA in cancer [318] . On the contrary, regarding p110  no specific 
roles have been described so far.  
Having demonstrated that PI3K class IA and class IB are crucial in migration and proliferation 
of breast cancer, we considered the subset of proteins that could have been probable targets of 
PI3KCA and PI3KCB. We demonstrated that the activity of S6K, cdc42 and Rac was 
drastically reduced after inhibition of p110  and p110 . We also showed that these three 
proteins drastically affect migration. These observations together proved for the first time that 
p110  and p110  directly activated S6K, cdc42 and Rac and that this pathway induces 
breast cancer cell migration. The fact that they induce migration was not surprising since 
especially for cdc42 and Rac it is commonly known that these proteins are involved in actin 
rearrangements and thereby in affecting cell tumor migration [320-322]. Regarding their 
functions in breast cancer less is known but their crucial role seems to be accepted [323]. The 
literature reporting about S6K and migration is really scarce but this enzyme may also be 
important in cell migration [324], although it has a different role from actin reorganization 
[325]. Together with these observations is known that S6K, cdc42 and Rac are downstream 
targets of PI3Ks [200, 326]. 
Together with p110  and p110  there is a third catalytic subunit in class IA PI3K, namely 
p110 . The ed to be antagonist of p110  and p110 . In fact its 
expression was detectable only in EpH4 and not in EpRas and FibRas cells. We demonstrated 
that when restoring its expression in EpRas and FibRas, cellular migration was drastically 
impaired. These results were quite surprising, since they are in contrast with some other 
studies already published [327]. However, reports about p110  in cancer cell migration are 
few and ours is the first regarding specifically breast cancer.  
The Rho protein is largely accepted to be crucial in increasing cell adhesion, thereby in 
inhibiting migration [328]. In accordance with this widely accepted model, we confirmed that 
its overexpression reduces breast cancer cells migration. This suggests that Rho could 
definitely be a possible target downstream of p110 . Even if nothing is known regarding this  
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, Rho is generally considered a downstream protein of the PI3K pathway 
[329]. Here for the first time we evidenciated a selective regulation of p110  and Rho, in fact 
ir Rho activity. We also found that p110  
expression induces AKT activation. Therefore we decided to test the ability of AKT to impair 
cell migration in breast cancer. These results evidenced a negative impact on migration. AKT 
is an already well known protein activated by PI3K [330]. The last result confirmed the role 
 in inducing Rho and AKT activation and reducing migration. Here for the first time 
we classified this role as being specific for p110  isoform. This study reports novel findings 
in the field of class I PI3K isoforms and their signaling pathway activation. From a clinical 
point of view these findings offer knowledge for developing new anticancer treatments that 
would be more specific, thereby more efficient and presenting less side effects.  
 
In other studies, we focalized our attention on the class II PI3KC2  isoform. This protein is a 
member of the class II PI3Ks and comparing to the class I PI3K, very little is known about it. 
PI3KC2  have been shown to be targets of the EGFR in human 
carcinoma-derived A431 cells. In fact after stimulation of these cells with EGF the activity of 
was significantly increased [331]. About the mechanism of this activation nothing 
was proved yet. Many models already demonstrated to be valid for class I activation by the 
EGFR could be valid also for class II PI3K members. In fact it was already demonstrated that 
the EGFR is able to recruit the p85 regulatory subunit to the membrane and thereby activate 
PI3K catalytic activity [332]. Different models were suggested for this recruitment. It was 
already demonstrated that this RTK is able to directly recruit and bind p85 through its SH2 
domain [152]. But since this domain is missing in class II PI3K, this model was not 
applicable. it was then discovered that the EGFR also recruits some adaptor proteins and that 
through these it can then recruit p85. The adaptor protein suggested for this role are the 
Abi1/Grb2/Eps8 complex [332, 333]. Following this observation we tested the possible 
involvement of this complex also in activating PI3KC2 . We could demonstrate that after 
cell stimulation with EGF, PI3KC2  was detected in the immunoprecipitated fraction of the 
Eps8/Abi1/Sos complex. This clearly proved the novel idea that EGFR recruit PI3KC2  by 
employing the adaptor complex Eps8/Abi1/Sos. In the literature, other adaptor proteins like 
Grb2 and Shc have been described in addition to this complex. Because of this we also 
investigated their possible involvement in our model. What we observed is that also Grb2 and  
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Shc can form a complex with PI3KC2 and induce its activation. We then further 
demonstrated for the first time that in human carcinoma cell lines Shc/Grb2/PI3KC2 and 
PI3KC2/Eps8/Abi1/Sos1 complexes, are in reality only one macromolecular complex and 
not two. We also proved that this complex is able to transducer the EGFR signal, down to the 
PI3KC2. Going on investigating possible downstream targets of PI3KC2 we could clearly 
show that after EGF stimulation also the activity of Rac was increased. This activity of Rac 
resulted in upregulation of cell migration. This last evidence was in reality expected, since 
Rac activation induced by PI3K class I has been largely described. In addition, the crucial role 
played in migration by Rac is already accepted [321]. In this report, we also proved for the 
first time that PI3KC2 recruitment also renders A-431 cells resistant to anoikis. Not much is 
known about Rac and anoikis, but what is described until now suggest the possibility that 
resistance to anoikis can be induced by two pathways, one involving Rac and another 
independent from this protein. This evidence was  reported in epithelial cells, therefore our 
results are the first experiments in carcinoma cell lines [334]. 
 
An additional study on PI3KC2 revealed that this protein also contributes to the regulation 
of proliferation and survival in several tumors. In fact the expression pattern and functions of 
the PI3KC2isoform were investigated in a panel of tumour samples and cell lines. 
Overexpression of PI3KC2was found in subsets of tumours and cell lines from acute 
myeloid leukemia (AML), glioblastoma multiforme (GBM), medulloblastoma (MB), 
neuroblastoma (NB), and small cell lung cancer (SCLC). The treatment of these tumor 
samples and cell lines with pharmacological inhibitors for PI3KC2 (PI701 and PI702) led to 
a dose-dependent inhibition of proliferation. The same results were obtained silencing PI3K 
C2 by siRNA. These effects of PI3KC2 on cellular responses were tested in a large number 
of cancer cell lines and ex-vivo cultures. These studies clearly demonstrated that this protein 
plays a crucial role in several cell activities, such as proliferation and migration. These 
properties were critically impared when together with the PI3KC2 pharmacological 
inhibitor, a chemotherapeutic agent, like doxorubicin, was added. Our recent results in 
HEK293 cells also proved that PI3KC2 activation can be achieved through Src protein 
recruitment. The ability of Src to activate PI3Ks is already known, even if, also in this case, 
all the observations concern class I PI3K members. The activation of PI3KC2 through Src  
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increase migration and proliferation of HEK293 cells. Furder experiments are now going on 
in order to identify which phosphorylation site in PI3KC2 is crucial for its activation. 
 
In summary, all these studies demonstrate that all the components of PI3K class I can regulate 
different functions in cancer cells. This offers new knowledge about PI3K signaling and could 
offer new ideas for developing novel therapeutic strategies, more specific and thereby with 
less side effects. In fact, one of the most important problems in breast cancer is that many 
treatments used until now have very strong and delayed side effects, which are much worse 
than their advantages in breast cancer treatment.  
 
All the results concerning PI3KC2 roles and tissue-specific distribution, taken together can 
be fundamental for a better understanding tumor progression, offering then, again a new 
opportunity for developing isoforms-specific PI3K inhibitors hopefully usable in new 
therapies. 
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5    Review articles 
5.1  Lipid Rafts and Caveolae in Signaling by Growth Factor Receptors 
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5.2 Recent Patent of Gene Sequences Relative to the 
Phosphatidylinositol 3-kinase/Akt Pathway and  
their Relevance to Drug Discovery 
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